{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How should sertraline dosing be adjusted for an individual with the SLC6A4 l/l genotype?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"sertraline\", \"Gene Name\": \"SLC6A4\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf\", \"Content to Search\": \"Dose adjustment protocol for sertraline based on SLC6A4 5-HTTLPR genotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How do CYP2B6 genotypes map to cyclophosphamide bioactivation phenotypes?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the function of the ABCG2 transporter in the excretion of allopurinol and its metabolite, oxypurinol?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the trimipramine dosing recommendation for a patient who is a CYP2D6 poor metabolizer and is taking a concurrent CYP2D6 inhibitor?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"trimipramine\", \"Gene Name\": \"CYP2D6\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium Guideline (CPICÂ®) for CYP2D6 and CYP2C19 Genotypes and Dosing of Tricyclic Antidepressants: 2016 Update (December 2016).pdf\", \"Content to Search\": \"Dosing guidance for trimipramine in CYP2D6 poor metabolizers with a drug-drug interaction involving a CYP2D6 inhibitor\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the increased risk of hyperlipidemia and CNS effects with lorlatinib in patients with reduced CYP3A4 function?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the function of the CYP3A5 enzyme in the metabolism of pravastatin?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"pravastatin\", \"Gene Name\": \"CYP3A5\", \"CPIC Guideline Name\": \"The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf\", \"Content to Search\": \"Description of CYP3A5's role in pravastatin metabolism.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the recommended fluoxetine dose for a CYP2B6 poor metabolizer?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"fluoxetine\", \"Gene Name\": \"CYP2B6\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf\", \"Content to Search\": \"Dose adjustment protocol for fluoxetine in CYP2B6 poor metabolizers.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the function of the OATP1B1 transporter in the hepatic uptake of remdesivir?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What are the target trough concentrations for everolimus in a patient with a CYP3A4 rapid metabolizer phenotype?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the dosing recommendation for metoprolol in patients with heart failure and the ADRA2C Ins/Del polymorphism?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"metoprolol\", \"Gene Name\": \"ADRA2C\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf\", \"Content to Search\": \"Dosing guidelines for metoprolol in heart failure patients, adjusted for ADRA2C genotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How do CYP2D6 genotypes map to chloroquine metabolism phenotypes?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the recommended dose adjustment for desipramine based on a patient's CYP1A2 metabolizer status?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How does the CYP2C9*3 allele affect the pharmacokinetics of aspirin?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"aspirin\", \"Gene Name\": \"CYP2C9\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf\", \"Content to Search\": \"Pharmacokinetic data on aspirin related to the CYP2C9*3 allele.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the quantified risk of acute kidney injury for ketorolac users with the CYP2C9*2/*3 genotype?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the function of organic anion transporters (OATs) in the renal elimination of meropenem?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the recommended dose of modafinil for a patient who is a CYP3A4 poor metabolizer?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the function of the CYP2C9 enzyme in the metabolic clearance of fluconazole?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the suggested therapeutic range for plasma endoxifen concentrations in a patient who is a CYP2C9 intermediate metabolizer?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the increased risk of heart failure hospitalization with saxagliptin in patients with reduced CYP3A4 function?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the recommended dose of cholestyramine for a patient with a specific variant in the bile acid receptor (FXR/NR1H4) gene?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the increased risk of systemic corticosteroid effects (e.g., adrenal suppression) with inhaled fluticasone in patients with reduced CYP3A4 function?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What OPRM1 variants are associated with altered naltrexone response?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"naltrexone\", \"Gene Name\": \"OPRM1\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf\", \"Content to Search\": \"List and description of OPRM1 variants and their corresponding functional impact on naltrexone response.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the function of the GRK4 enzyme in the context of nebivolol therapy?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"nebivolol\", \"Gene Name\": \"GRK4\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf\", \"Content to Search\": \"Explanation of GRK4's role in desensitizing adrenergic receptors and its influence on nebivolol efficacy.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the risk of reduced efficacy of oseltamivir in individuals with high-activity CES1 variants?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the mechanism by which sulfacetamide causes oxidative stress leading to hemolysis in G6PD deficient individuals?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"sulfacetamide\", \"Gene Name\": \"G6PD\", \"CPIC Guideline Name\": \"Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf\", \"Content to Search\": \"Biochemical mechanism of sulfacetamide-induced oxidative damage to red blood cells in the context of G6PD deficiency.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the suggested therapeutic range for plasma vemurafenib concentrations in a CYP3A4 rapid metabolizer?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the recommended fluvastatin dose for a CYP2C9 poor metabolizer?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"fluvastatin\", \"Gene Name\": \"CYP2C9\", \"CPIC Guideline Name\": \"The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf\", \"Content to Search\": \"Dose adjustment protocol for fluvastatin in CYP2C9 poor metabolizers.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How should tadalafil dosing be adjusted for a patient who is a CYP3A4 poor metabolizer?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How should ticagrelor dosing be adjusted for a CYP3A4 poor metabolizer?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the recommended escitalopram dose for a CYP2B6 poor metabolizer?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"escitalopram\", \"Gene Name\": \"CYP2B6\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf\", \"Content to Search\": \"Dose adjustment protocol for escitalopram in CYP2B6 poor metabolizers.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the dosing recommendation for sotalol in elderly patients with heart failure and the GRK5 Leu41 variant?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"sotalol\", \"Gene Name\": \"GRK5\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf\", \"Content to Search\": \"Dosing guidelines for sotalol in elderly heart failure patients, adjusted for GRK5 genotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the recommended pindolol dose for an individual with a GRK4 variant associated with altered response?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"pindolol\", \"Gene Name\": \"GRK4\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf\", \"Content to Search\": \"Dose adjustment protocol for pindolol based on GRK4 genotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the increased risk of adverse effects for a CYP2B6 ultrarapid metabolizer taking citalopram?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"citalopram\", \"Gene Name\": \"CYP2B6\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf\", \"Content to Search\": \"Quantified risk data for adverse effects or lack of efficacy in CYP2B6 ultrarapid metabolizers using citalopram.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the suggested therapeutic range for plasma sufentanil concentrations in a CYP2D6 intermediate metabolizer?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"sufentanil\", \"Gene Name\": \"CYP2D6\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf\", \"Content to Search\": \"Plasma concentration ranges for sufentanil in CYP2D6 intermediate metabolizers.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the suggested therapeutic strategy for a patient whose tumor has a KRAS G12D mutation, regarding cetuximab therapy?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the increased risk of cardiovascular adverse effects for a CYP2D6 poor metabolizer taking atomoxetine?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"atomoxetine\", \"Gene Name\": \"CYP2D6\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 Genotype and Atomoxetine (February 2019).pdf\", \"Content to Search\": \"Quantified risk data for adverse effects like increased blood pressure or tachycardia in CYP2D6 poor metabolizers\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the increased risk of neurological side effects with mexiletine in individuals with reduced CYP2D6 function?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the function of Carboxylesterase 2 (CES2) in the activation pathway of the prodrug capecitabine?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the quantified risk of next-day cognitive impairment for eszopiclone users with decreased CYP3A4 activity?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the dosing recommendation for axitinib in advanced renal cell carcinoma patients with known CYP3A4 variants?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What are the known functional classifications of CYP2C8 alleles relevant to NSAID metabolism?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"nabumetone\", \"Gene Name\": \"CYP2C8\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf\", \"Content to Search\": \"Allele function table or definitions for CYP2C8.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the function of the ADRA2C gene product in the context of metoprolol therapy?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"metoprolol\", \"Gene Name\": \"ADRA2C\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf\", \"Content to Search\": \"Explanation of ADRA2C's role as an alpha-2C adrenergic receptor and its influence on the sympathetic nervous system and beta-blocker effects.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the recommended dose of everolimus for a patient who is a CYP3A4 poor metabolizer?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What diplotypes define a CYP3A5 intermediate metabolizer for cyclosporine therapy according to CPIC?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the function of the CYP2C19 enzyme in the metabolism of duloxetine?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"duloxetine\", \"Gene Name\": \"CYP2C19\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf\", \"Content to Search\": \"Description of CYP2C19's role in the metabolic pathway of duloxetine.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the increased risk of muscle spasms and alopecia with vismodegib in individuals with CYP2C9*3 alleles?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the increased risk of adverse effects with benralizumab in individuals with specific IL5RA variants?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What are the target plasma concentrations for ketorolac in a patient with a CYP2C9 intermediate metabolizer phenotype?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the increased risk of cardiovascular events (e.g., palpitations, tachycardia) with anagrelide in individuals with reduced CYP1A2 function?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "Which CACNA1S genotypes are associated with Malignant Hyperthermia Susceptibility?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"desflurane\", \"Gene Name\": \"CACNA1S\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for the use of potent volatile anesthetic agents and succinylcholine in the context of RYR1 or CACNA1S genotypes.pdf\", \"Content to Search\": \"Diplotype or allele definitions for CACNA1S that correspond to the Malignant Hyperthermia Susceptible phenotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the likelihood of treatment failure with peginterferon alfa-2a for a patient with the unfavorable IFNL4-ÎG allele?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"peginterferon alfa-2a\", \"Gene Name\": \"IFNL4\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for IFNL3 (IL28B) Genotype and PEG interferon-alpha-based Regimens (February 2014).pdf\", \"Content to Search\": \"Quantified risk of non-response or relapse in patients with the IFNL4-ÎG allele treated with peginterferon alfa-2a\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the mechanism by which sulfadimidine causes oxidative stress leading to hemolysis in G6PD deficient individuals?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"sulfadimidine\", \"Gene Name\": \"G6PD\", \"CPIC Guideline Name\": \"Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf\", \"Content to Search\": \"Biochemical mechanism of sulfadimidine-induced oxidative damage to red blood cells in the context of G6PD deficiency.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How should remdesivir dosing be adjusted for a patient with a SLCO1B1 low-function genotype?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the function of the Cytochrome P450 Oxidoreductase (POR) enzyme in supporting the activity of CYP3A enzymes that metabolize tacrolimus?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the quantified risk of altered therapeutic response for an individual with the GRK5 Gln41Leu polymorphism taking carvedilol?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"carvedilol\", \"Gene Name\": \"GRK5\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf\", \"Content to Search\": \"Quantified risk data for altered efficacy in individuals with the GRK5 Gln41Leu polymorphism taking carvedilol.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the risk of hyperkalemia with losartan in CYP2C9 poor metabolizers?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the increased risk of SAMS for a CYP2C9 poor metabolizer taking lovastatin?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"lovastatin\", \"Gene Name\": \"CYP2C9\", \"CPIC Guideline Name\": \"The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf\", \"Content to Search\": \"Quantified risk data for SAMS in CYP2C9 poor metabolizers using lovastatin.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What are the anesthetic recommendations for a pediatric patient with a CACNA1S genotype conferring Malignant Hyperthermia Susceptibility?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"succinylcholine\", \"Gene Name\": \"CACNA1S\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for the use of potent volatile anesthetic agents and succinylcholine in the context of RYR1 or CACNA1S genotypes.pdf\", \"Content to Search\": \"Anesthetic agent selection and dosing for pediatric patients with CACNA1S-MHS.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What are the expected hematological changes in a G6PD deficient individual exposed to probenecid?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"probenecid\", \"Gene Name\": \"G6PD\", \"CPIC Guideline Name\": \"Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf\", \"Content to Search\": \"Data on hematological parameters in G6PD deficient individuals after probenecid administration.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the quantified risk of altered therapeutic response for an individual with the GRK4 A142V polymorphism taking esmolol?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"esmolol\", \"Gene Name\": \"GRK4\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf\", \"Content to Search\": \"Quantified risk data for altered efficacy in individuals with GRK4 variants taking esmolol.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the basic mechanism of itraconazole's potent inhibition of the CYP3A4 enzyme?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the increased risk of adverse effects for a CYP2D6 poor metabolizer taking a standard dose of fluvoxamine?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"fluvoxamine\", \"Gene Name\": \"CYP2D6\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf\", \"Content to Search\": \"Quantified risk data for adverse effects in CYP2D6 poor metabolizers using fluvoxamine.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "Which diplotypes define a CYP2C9 poor metabolizer?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"aspirin\", \"Gene Name\": \"CYP2C9\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf\", \"Content to Search\": \"Diplotype definitions for the CYP2C9 poor metabolizer phenotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the dosing recommendation for fentanyl in patients with cancer pain and an OPRM1 variant associated with decreased receptor function?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"fentanyl\", \"Gene Name\": \"OPRM1\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf\", \"Content to Search\": \"Dosing guidelines for fentanyl in cancer patients, adjusted for OPRM1 genotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the dosing recommendation for sertraline in an elderly patient with a CYP2C19 poor metabolizer phenotype?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"sertraline\", \"Gene Name\": \"CYP2C19\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf\", \"Content to Search\": \"Dosing adjustments for sertraline in elderly CYP2C19 poor metabolizers.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the increased risk of ototoxicity from cisplatin in individuals with specific TPMT variants?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the expected clinical response to levomilnacipran in a patient with the HTR2A rs7997012 G/G genotype?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"levomilnacipran\", \"Gene Name\": \"HTR2A\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf\", \"Content to Search\": \"Pharmacodynamic data, such as remission rates, for levomilnacipran stratified by HTR2A rs7997012 genotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What are the target plasma concentrations for ripretinib in a patient with a CYP3A4 rapid metabolizer phenotype?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What are the expected plasma concentrations of levomilnacipran in a CYP2C19 ultrarapid metabolizer?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"levomilnacipran\", \"Gene Name\": \"CYP2C19\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf\", \"Content to Search\": \"Plasma concentration ranges or AUC data for levomilnacipran in CYP2C19 ultrarapid metabolizers.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How do CYP2C9 genotypes map to apixaban metabolism phenotypes?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the risk of treatment failure with romiplostim in immune thrombocytopenia (ITP) patients with MPL mutations?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the risk of poor response to paroxetine in individuals with the high-activity COMT 'Val' allele?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the function of HMGCR in the mechanism of action of pitavastatin?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"pitavastatin\", \"Gene Name\": \"HMGCR\", \"CPIC Guideline Name\": \"The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf\", \"Content to Search\": \"Description of HMGCR as the pharmacological target of pitavastatin.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What are the expected plasma concentrations of fluvoxamine in a CYP2D6 ultrarapid metabolizer?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"fluvoxamine\", \"Gene Name\": \"CYP2D6\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf\", \"Content to Search\": \"Plasma concentration ranges or AUC data for fluvoxamine in CYP2D6 ultrarapid metabolizers.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the function of the ADRB1 gene product in the context of sotalol therapy?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"sotalol\", \"Gene Name\": \"ADRB1\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf\", \"Content to Search\": \"Explanation of ADRB1's role as the beta-1 adrenergic receptor, a primary target for sotalol.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the recommended desvenlafaxine dose for a CYP2D6 poor metabolizer?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"desvenlafaxine\", \"Gene Name\": \"CYP2D6\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf\", \"Content to Search\": \"Dose adjustment protocol for desvenlafaxine in CYP2D6 poor metabolizers.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the quantified risk of malignant hyperthermia when administering succinylcholine to a patient with a pathogenic CACNA1S variant?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"succinylcholine\", \"Gene Name\": \"CACNA1S\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for the use of potent volatile anesthetic agents and succinylcholine in the context of RYR1 or CACNA1S genotypes.pdf\", \"Content to Search\": \"Incidence rates or risk data for succinylcholine-triggered malignant hyperthermia in patients with pathogenic CACNA1S variants.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the dosing recommendation for simvastatin in pediatric patients with a CYP3A4 poor metabolizer phenotype?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"simvastatin\", \"Gene Name\": \"CYP3A4\", \"CPIC Guideline Name\": \"The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf\", \"Content to Search\": \"Pediatric dosing adjustments for simvastatin in CYP3A4 poor metabolizers.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the recommended dose of cladribine for a patient with a specific variant in the DCK (deoxycytidine kinase) gene?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How should levomethadone dosing be adjusted for an individual with an OPRM1 variant associated with decreased receptor function (e.g., A118G)?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"levomethadone\", \"Gene Name\": \"OPRM1\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf\", \"Content to Search\": \"Dose adjustment protocol for levomethadone based on OPRM1 variants affecting receptor function.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How do SERPINC1 genotypes correlate with fondaparinux efficacy phenotypes?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What are the expected hematological changes in a G6PD deficient individual exposed to mepacrine?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"mepacrine\", \"Gene Name\": \"G6PD\", \"CPIC Guideline Name\": \"Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf\", \"Content to Search\": \"Data on hematological parameters in G6PD deficient individuals after mepacrine administration.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the dosing recommendation for amikacin in a pediatric patient with a pathogenic MT-RNR1 variant?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"amikacin\", \"Gene Name\": \"MT-RNR1\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for MT-RNR1 and Aminoglycosides (May 2021).pdf\", \"Content to Search\": \"Specific dosing guidance for amikacin in pediatric populations carrying pathogenic MT-RNR1 variants.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What are the target plasma concentrations of oseltamivir carboxylate (active metabolite) in a patient with a low-activity CES1 genotype?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the dosing recommendation for carvedilol in patients with hypertension and a GRK4 polymorphism associated with altered response?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"carvedilol\", \"Gene Name\": \"GRK4\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf\", \"Content to Search\": \"Dosing guidelines for carvedilol in hypertensive patients, adjusted for GRK4 genotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the mechanism by which tafenoquine causes oxidative stress leading to hemolysis in G6PD deficient individuals?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"tafenoquine\", \"Gene Name\": \"G6PD\", \"CPIC Guideline Name\": \"Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf\", \"Content to Search\": \"Biochemical mechanism of tafenoquine-induced oxidative damage to red blood cells in the context of G6PD deficiency.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the recommended dose of carvedilol for a patient with the ADRB2 Arg16Gly polymorphism?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the suggested therapeutic range for plasma naltrexone concentrations in a CYP2D6 intermediate metabolizer?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"naltrexone\", \"Gene Name\": \"CYP2D6\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf\", \"Content to Search\": \"Plasma concentration ranges for naltrexone in CYP2D6 intermediate metabolizers.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "Are there specific warfarin dosing considerations for patients with the CYP4F2*3 variant and comorbid liver disease?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"warfarin\", \"Gene Name\": \"CYP4F2\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for Pharmacogenetics-guided Warfarin Dosing: 2016 Update.pdf\", \"Content to Search\": \"Dosing adjustments for warfarin in patients with both CYP4F2*3 variant and liver comorbidities\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the expected increase in lornoxicam exposure (AUC) in a CYP2C9 poor metabolizer?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"lornoxicam\", \"Gene Name\": \"CYP2C9\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf\", \"Content to Search\": \"Pharmacokinetic data on lornoxicam exposure in CYP2C9 poor metabolizers.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the risk of a blunted heart rate response to carvedilol in individuals with the ADRB2 Gly16 variant?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the quantified risk of malignant hyperthermia when administering enflurane to a patient with a pathogenic RYR1 variant?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"enflurane\", \"Gene Name\": \"RYR1\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for the use of potent volatile anesthetic agents and succinylcholine in the context of RYR1 or CACNA1S genotypes.pdf\", \"Content to Search\": \"Incidence rates or risk data for enflurane-triggered malignant hyperthermia in patients with pathogenic RYR1 variants.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the risk of reduced therapeutic response for an individual homozygous for the ADRB1 Gly389 allele (Gly/Gly) when taking betaxolol?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"betaxolol\", \"Gene Name\": \"ADRB1\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf\", \"Content to Search\": \"Quantified risk data for reduced efficacy in ADRB1 Gly389/Gly389 individuals taking betaxolol.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the suggested therapeutic range for plasma hydroxybupropion concentrations in a CYP2B6 rapid metabolizer?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What ADRB2 polymorphisms are associated with altered beta-blocker response?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"carvedilol\", \"Gene Name\": \"ADRB2\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf\", \"Content to Search\": \"Definitions of ADRB2 variants (e.g., Gly16Arg, Gln27Glu) and their association with beta-blocker efficacy.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How do CYP2C8 genotypes map to enzalutamide metabolism phenotypes?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the recommended nadolol dose for an individual with a GRK4 variant associated with altered response?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"nadolol\", \"Gene Name\": \"GRK4\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf\", \"Content to Search\": \"Dose adjustment protocol for nadolol based on GRK4 genotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What diplotypes define a CYP3A4 intermediate metabolizer for alfentanil therapy?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the risk of non-response for an individual with the SLC6A4 s/s genotype taking sertraline?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"sertraline\", \"Gene Name\": \"SLC6A4\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf\", \"Content to Search\": \"Quantified risk or odds ratio for treatment non-response in sertraline users with the SLC6A4 s/s genotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the suggested therapeutic range for plasma rifampin concentrations in a patient with a high-function SLCO1B1 genotype?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "Which TPMT alleles are combined to define a poor metabolizer phenotype?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"mercaptopurine\", \"Gene Name\": \"TPMT\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium Guidelines for thiopurine dosing based on TPMT and NUDT15 genotypes: 2018 Update (November 2018).pdf\", \"Content to Search\": \"Allele or diplotype definitions for the TPMT poor metabolizer phenotype\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the suggested therapeutic range for plasma remdesivir concentrations in a patient with a high-function SLCO1B1 genotype?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the dosing recommendation for efavirenz in children weighing <40kg with a CYP2B6 poor metabolizer phenotype?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"efavirenz\", \"Gene Name\": \"CYP2B6\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2B6 and Efavirenz-containing Antiretroviral Therapy (April 2019).pdf\", \"Content to Search\": \"Pediatric dosing guidance for efavirenz in children under 40kg who are CYP2B6 poor metabolizers.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What diplotypes for CYP1A2 define a poor metabolizer in the context of duloxetine therapy?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the suggested therapeutic range for plasma dextrorphan (active metabolite) concentrations in a CYP2D6 ultrarapid metabolizer?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the function of the SLC6A4 gene product in the mechanism of action of fluvoxamine?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"fluvoxamine\", \"Gene Name\": \"SLC6A4\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf\", \"Content to Search\": \"Explanation of SLC6A4's role as the serotonin transporter, the primary target of fluvoxamine.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the recommended dose of nivolumab for a patient with a specific PD-L1 (CD274) gene polymorphism?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the dosing recommendation for tiotropium in patients with a history of poor response to other anticholinergics based on their genotype?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How do host genetic factors (e.g., in ABCB1) correlate with cefepime-induced encephalopathy?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the suggested therapeutic response (e.g., lipid reduction) for niacin based on a patient's HCAR2 genotype?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How should fentanyl dosing be adjusted for a CYP2D6 poor metabolizer?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"fentanyl\", \"Gene Name\": \"CYP2D6\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf\", \"Content to Search\": \"Dose adjustment protocol for fentanyl in CYP2D6 poor metabolizers.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How do UGT2B7 genotypes map to diclofenac clearance phenotypes?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What are the expected plasma nebivolol concentrations in a CYP2D6 ultrarapid metabolizer?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"nebivolol\", \"Gene Name\": \"CYP2D6\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf\", \"Content to Search\": \"Plasma concentration ranges or AUC data for nebivolol in CYP2D6 ultrarapid metabolizers.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the mechanism by which glimepiride causes oxidative stress leading to hemolysis in G6PD deficient individuals?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"glimepiride\", \"Gene Name\": \"G6PD\", \"CPIC Guideline Name\": \"Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf\", \"Content to Search\": \"Biochemical mechanism of glimepiride-induced oxidative damage to red blood cells in the context of G6PD deficiency.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the suggested therapeutic trough concentration for sirolimus in a CYP3A5 expresser versus a non-expresser?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How should palbociclib dosing be adjusted for a patient who is a CYP3A4 poor metabolizer?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What are the expected plasma sotalol concentrations in a CYP2D6 ultrarapid metabolizer?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"sotalol\", \"Gene Name\": \"CYP2D6\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf\", \"Content to Search\": \"Plasma concentration ranges or AUC data for sotalol in CYP2D6 ultrarapid metabolizers.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the dosing recommendation for tolbutamide in a diabetic patient with G6PD deficiency?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"tolbutamide\", \"Gene Name\": \"G6PD\", \"CPIC Guideline Name\": \"Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf\", \"Content to Search\": \"Dosing guidelines for tolbutamide in G6PD deficient patients with type 2 diabetes.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How should citalopram dosing be adjusted for an individual with the SLC6A4 L/L genotype?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"citalopram\", \"Gene Name\": \"SLC6A4\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf\", \"Content to Search\": \"Dosing or therapeutic recommendations for citalopram based on SLC6A4 5-HTTLPR genotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "Is glyburide (glibenclamide) contraindicated or should dosing be adjusted for a G6PD deficient individual?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"glyburide\", \"Gene Name\": \"G6PD\", \"CPIC Guideline Name\": \"Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf\", \"Content to Search\": \"Dosing protocol or contraindication for glyburide in G6PD deficient individuals.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the increased risk of peripheral neuropathy with teriflunomide in individuals with reduced CYP2C8 function?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the quantified risk of acute hemolytic anemia for a G6PD deficient individual taking doxorubicin?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"doxorubicin\", \"Gene Name\": \"G6PD\", \"CPIC Guideline Name\": \"Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf\", \"Content to Search\": \"Incidence rates or risk multipliers for acute hemolytic anemia with doxorubicin use in G6PD deficient patients.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the increased risk of SAMS for a CYP2C9 poor metabolizer taking fluvastatin?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"fluvastatin\", \"Gene Name\": \"CYP2C9\", \"CPIC Guideline Name\": \"The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf\", \"Content to Search\": \"Quantified risk data for SAMS in CYP2C9 poor metabolizers using fluvastatin.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the role of the COMT enzyme in the pharmacological response to levomethadone?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"levomethadone\", \"Gene Name\": \"COMT\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf\", \"Content to Search\": \"Mechanism of interaction between COMT enzyme activity and levomethadone's effects.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the increased risk of peripheral edema and interstitial lung disease with capmatinib in individuals with reduced CYP3A4 function?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What are the target plasma concentrations for guaifenesin in a patient with a hypothetical rapid metabolizer phenotype?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the suggested therapeutic range for plasma dasatinib concentrations in a CYP3A4 rapid metabolizer?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What are the expected pharmacodynamic effects on cardiac function in a patient with the GRK5 Gln41Gln genotype taking nebivolol?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"nebivolol\", \"Gene Name\": \"GRK5\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf\", \"Content to Search\": \"Pharmacodynamic data for nebivolol stratified by GRK5 genotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What are the expected pharmacodynamic effects on cardiac function in a patient with the GRK5 Gln41Gln genotype taking nadolol?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"nadolol\", \"Gene Name\": \"GRK5\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf\", \"Content to Search\": \"Pharmacodynamic data for nadolol stratified by GRK5 genotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the role of the CYP2C19 enzyme in the metabolic clearance of lansoprazole?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "Are there combined CYP2C8 and CYP2C9 genotype considerations for ibuprofen dosing in pediatric patients?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"ibuprofen\", \"Gene Name\": \"CYP2C8\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf\", \"Content to Search\": \"Guidance on combined CYP2C8/CYP2C9 genotypes for ibuprofen therapy in pediatric populations.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the suggested therapeutic range for plasma pralsetinib concentrations in a CYP3A4 rapid metabolizer?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What G6PD genotypes are classified as deficient (e.g., Class I, II, or III variants)?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"glipizide\", \"Gene Name\": \"G6PD\", \"CPIC Guideline Name\": \"Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf\", \"Content to Search\": \"Definitions of G6PD genotypes and their classification into different functional/phenotypic classes of deficiency.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the dosing recommendation for naltrexone in patients with alcohol use disorder and an OPRM1 variant associated with decreased receptor function?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"naltrexone\", \"Gene Name\": \"OPRM1\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf\", \"Content to Search\": \"Dosing guidelines for naltrexone in alcohol use disorder patients, adjusted for OPRM1 genotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the dosing recommendation for vemurafenib in melanoma patients with known CYP3A4 variants?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What OPRM1 variants are associated with altered fentanyl response?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"fentanyl\", \"Gene Name\": \"OPRM1\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf\", \"Content to Search\": \"List and description of OPRM1 variants and their corresponding functional impact on fentanyl response.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How should duloxetine dosing be adjusted for an individual with the SLC6A4 L/L genotype?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"duloxetine\", \"Gene Name\": \"SLC6A4\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf\", \"Content to Search\": \"Dosing or therapeutic recommendations for duloxetine based on SLC6A4 5-HTTLPR genotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the dosing recommendation for chloroquine in a pediatric patient with G6PD deficiency?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"chloroquine\", \"Gene Name\": \"G6PD\", \"CPIC Guideline Name\": \"Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf\", \"Content to Search\": \"Pediatric-specific dosing guidelines for chloroquine in G6PD deficient children.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How should rosuvastatin dosing be adjusted for a patient with a CYP2D6 poor metabolizer phenotype?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What are the expected pharmacodynamic effects on blood pressure in a patient with the ADRB2 Gly16Arg polymorphism taking nadolol?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"nadolol\", \"Gene Name\": \"ADRB2\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf\", \"Content to Search\": \"Pharmacodynamic data for nadolol stratified by ADRB2 genotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What diplotypes define a CYP2D6 normal metabolizer?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"oxycodone\", \"Gene Name\": \"CYP2D6\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf\", \"Content to Search\": \"Diplotype definitions and activity scores for the CYP2D6 normal metabolizer phenotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the function of the CYP2C19 enzyme in the metabolism of fluvoxamine?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"fluvoxamine\", \"Gene Name\": \"CYP2C19\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf\", \"Content to Search\": \"Description of CYP2C19's role in the metabolic pathway of fluvoxamine.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How do CYP1A2 genotypes map to theophylline clearance phenotypes?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What are the target plasma concentrations of acetaminophen sulfate in a patient with a high-activity SULT1A1 genotype?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the function of HMGCR in the mechanism of action of rosuvastatin?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"rosuvastatin\", \"Gene Name\": \"HMGCR\", \"CPIC Guideline Name\": \"The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf\", \"Content to Search\": \"Description of HMGCR as the pharmacological target of rosuvastatin.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What are the expected hematological changes in a G6PD deficient individual exposed to moxifloxacin?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"moxifloxacin\", \"Gene Name\": \"G6PD\", \"CPIC Guideline Name\": \"Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf\", \"Content to Search\": \"Data on hematological parameters in G6PD deficient individuals after moxifloxacin administration.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the mechanism by which MT-RNR1 variants increase susceptibility to streptomycin-induced ototoxicity?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"streptomycin\", \"Gene Name\": \"MT-RNR1\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for MT-RNR1 and Aminoglycosides (May 2021).pdf\", \"Content to Search\": \"Functional explanation of how MT-RNR1 variants interact with streptomycin to cause cellular damage.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What HMGCR variants are associated with altered statin response?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"fluvastatin\", \"Gene Name\": \"HMGCR\", \"CPIC Guideline Name\": \"The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf\", \"Content to Search\": \"Definitions of HMGCR variants or genotypes associated with altered statin efficacy.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How do CYP2D6 genotypes map to celecoxib metabolism phenotypes?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the function of the hERG potassium channel (encoded by KCNH2) and how is it affected by azithromycin?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "Is chlorpropamide contraindicated or should dosing be adjusted for a G6PD deficient individual?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"chlorpropamide\", \"Gene Name\": \"G6PD\", \"CPIC Guideline Name\": \"Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf\", \"Content to Search\": \"Dosing protocol or contraindication for chlorpropamide in G6PD deficient individuals.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the expected clinical response (pharmacodynamics) for a patient with the SLC6A4 l/s genotype taking venlafaxine?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"venlafaxine\", \"Gene Name\": \"SLC6A4\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf\", \"Content to Search\": \"Pharmacodynamic data (e.g., remission rates) for venlafaxine based on SLC6A4 5-HTTLPR genotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the suggested therapeutic range for plasma glasdegib concentrations in a CYP3A4 rapid metabolizer?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What diplotypes for UGT2B7 define a poor metabolizer in the context of indomethacin therapy?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the recommended dose of dolutegravir for a patient with a UGT1A1*28 allele?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the suggested therapeutic range for plasma ticagrelor concentrations in a CYP3A4 rapid metabolizer?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the role of the CYP2C9 enzyme in the metabolism of lornoxicam?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"lornoxicam\", \"Gene Name\": \"CYP2C9\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf\", \"Content to Search\": \"Description of CYP2C9's function in lornoxicam's metabolic pathway.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the recommended dose of brigatinib for a patient who is a CYP2C8 poor metabolizer?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the function of the FCGR3A receptor in mediating the antibody-dependent cell-mediated cytotoxicity of ocrelizumab?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the function of the thrombopoietin receptor (MPL), the target of romiplostim, in megakaryopoiesis?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the recommended simvastatin dose for an individual with an HMGCR variant associated with reduced statin response?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"simvastatin\", \"Gene Name\": \"HMGCR\", \"CPIC Guideline Name\": \"The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf\", \"Content to Search\": \"Dose adjustment protocol for simvastatin based on HMGCR genotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the increased risk of euglycemic diabetic ketoacidosis with canagliflozin in individuals with low-activity UGT1A9 variants?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the recommended dose of saxagliptin for a patient who is a CYP3A4 poor metabolizer?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What are the expected pharmacodynamic effects (e.g., change in blood pressure) in a patient with a GRK4 polymorphism taking labetalol?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"labetalol\", \"Gene Name\": \"GRK4\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf\", \"Content to Search\": \"Pharmacodynamic data for labetalol stratified by GRK4 genotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the target therapeutic trough concentration range for tacrolimus?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"tacrolimus\", \"Gene Name\": \"CYP3A5\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for CYP3A5 genotype and Tacrolimus Dosing (July 2015).pdf\", \"Content to Search\": \"Therapeutic trough concentration range for tacrolimus\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the role of the COMT enzyme in the pharmacological response to remifentanil?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"remifentanil\", \"Gene Name\": \"COMT\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf\", \"Content to Search\": \"Mechanism of interaction between COMT enzyme activity and remifentanil's effects.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What genotypes define the COMT 'low-activity' phenotype?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"naltrexone\", \"Gene Name\": \"COMT\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf\", \"Content to Search\": \"Genotype definitions and corresponding diplotypes for the COMT low-activity phenotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the dosing recommendation for palbociclib in breast cancer patients with known CYP3A4 variants?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What diplotypes define a CYP3A5 normal metabolizer (expresser)?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"atorvastatin\", \"Gene Name\": \"CYP3A5\", \"CPIC Guideline Name\": \"The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf\", \"Content to Search\": \"Diplotype definitions for the CYP3A5 normal metabolizer (expresser) phenotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How should abiraterone acetate dosing be adjusted for a patient with a specific SULT2A1 gene variant?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the role of the CACNA1S gene in the mechanism of enflurane-triggered malignant hyperthermia?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"enflurane\", \"Gene Name\": \"CACNA1S\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for the use of potent volatile anesthetic agents and succinylcholine in the context of RYR1 or CACNA1S genotypes.pdf\", \"Content to Search\": \"Explanation of the CACNA1S gene function and its role in the pathophysiology of enflurane-induced malignant hyperthermia.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What are the expected plasma morphine concentrations (from codeine) in a patient with a COMT low-activity genotype?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"codeine\", \"Gene Name\": \"COMT\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf\", \"Content to Search\": \"Therapeutic range or plasma concentration data for morphine (active metabolite of codeine) stratified by COMT genotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What G6PD genotypes are classified as deficient (e.g., Class I, II, or III variants)?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"dapsone\", \"Gene Name\": \"G6PD\", \"CPIC Guideline Name\": \"Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf\", \"Content to Search\": \"Definitions of G6PD genotypes and their classification into different functional/phenotypic classes of deficiency.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "Are there specific methadone dosing recommendations for pregnant patients who are CYP2B6 poor metabolizers?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"methadone\", \"Gene Name\": \"CYP2B6\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium Guideline for CYP2B6 Genotype and Methadone Therapy (July 2024).pdf\", \"Content to Search\": \"Dosing adjustments for methadone in pregnant patients with CYP2B6 poor metabolizer status.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How should sildenafil dosing be adjusted for a CYP3A4 poor metabolizer?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the dosing recommendation for metoprolol in elderly patients with heart failure and the GRK5 Leu41 variant?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"metoprolol\", \"Gene Name\": \"GRK5\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf\", \"Content to Search\": \"Dosing guidelines for metoprolol in elderly heart failure patients, adjusted for GRK5 genotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How do UGT1A9 genotypes correlate with dapagliflozin efficacy and safety phenotypes?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the dosing recommendation for escitalopram in adolescents with the SLC6A4 S/S genotype?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"escitalopram\", \"Gene Name\": \"SLC6A4\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf\", \"Content to Search\": \"Dosing guidelines for escitalopram in adolescent patients, adjusted for SLC6A4 genotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the function of Cytotoxic T-Lymphocyte-Associated Protein 4 (CTLA-4), the target of ipilimumab, and how do its variants alter immune response?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the increased risk of cardiotoxicity with doxorubicin in individuals with low-function SLC22A16 transporter variants?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the target level of Ikaros/Aiolos degradation for a thalidomide-treated patient based on their CRBN genotype?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the expected clinical response (pharmacodynamics) for a patient with the SLC6A4 l/s genotype taking sertraline?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"sertraline\", \"Gene Name\": \"SLC6A4\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf\", \"Content to Search\": \"Pharmacodynamic data (e.g., remission rates) for sertraline based on SLC6A4 5-HTTLPR genotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the recommended initial dose of tenoxicam for a patient with a CYP2C9 poor metabolizer phenotype?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"tenoxicam\", \"Gene Name\": \"CYP2C9\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf\", \"Content to Search\": \"Dose adjustment protocol for tenoxicam in CYP2C9 poor metabolizers.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How should dapagliflozin dosing be adjusted for a patient with a UGT1A9 promoter polymorphism?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What are the target plasma concentrations for simvastatin acid in a patient with the ABCB1 3435C>T polymorphism?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the function of the CYP2C19 enzyme in the bioactivation of the prodrug proguanil?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the suggested therapeutic range for plasma pravastatin concentrations in a patient with a specific UGT1A1 diplotype?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How do SLC22A2 genotypes map to memantine renal clearance phenotypes?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the function of the CYP2D6 enzyme in the metabolism of labetalol?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"labetalol\", \"Gene Name\": \"CYP2D6\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf\", \"Content to Search\": \"Description of CYP2D6's role in labetalol metabolism.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What MT-RNR1 variants define a high-risk phenotype for aminoglycoside-induced hearing loss?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"plazomicin\", \"Gene Name\": \"MT-RNR1\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for MT-RNR1 and Aminoglycosides (May 2021).pdf\", \"Content to Search\": \"List of specific MT-RNR1 variants or diplotypes associated with increased risk of ototoxicity.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the quantified risk of altered therapeutic response for an individual with the ADRB2 Gln27Glu polymorphism when taking metoprolol?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"metoprolol\", \"Gene Name\": \"ADRB2\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf\", \"Content to Search\": \"Risk multipliers or clinical data on the efficacy of metoprolol in patients with the ADRB2 Gln27Glu polymorphism.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the increased risk of delayed onset of action with lisdexamfetamine in individuals with genetic variants affecting its hydrolysis?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What diplotypes define a CYP3A4 intermediate metabolizer for quinine therapy?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How does the metabolic pathway of thioguanine differ from azathioprine and mercaptopurine with respect to TPMT's role?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"thioguanine\", \"Gene Name\": \"TPMT\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium Guidelines for thiopurine dosing based on TPMT and NUDT15 genotypes: 2018 Update (November 2018).pdf\", \"Content to Search\": \"Comparison of thiopurine metabolic pathways and the specific role of TPMT for thioguanine\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the expected clinical response to citalopram in a patient with the SLC6A4 L/S genotype?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"citalopram\", \"Gene Name\": \"SLC6A4\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf\", \"Content to Search\": \"Pharmacodynamic data, such as remission rates, for citalopram stratified by SLC6A4 5-HTTLPR genotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the function of the CYP2D6 enzyme in the hydroxylation of tropisetron?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What are the expected plasma pitavastatin concentrations in a CYP2C9 intermediate metabolizer?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"pitavastatin\", \"Gene Name\": \"CYP2C9\", \"CPIC Guideline Name\": \"The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf\", \"Content to Search\": \"Plasma concentration ranges or AUC data for pitavastatin in CYP2C9 intermediate metabolizers.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the function of the CYP2C9 enzyme in the metabolic pathway of metronidazole?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the risk of treatment failure with fondaparinux in individuals with congenital antithrombin deficiency?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What are the expected plasma sertraline concentrations in a CYP2D6 ultrarapid metabolizer?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"sertraline\", \"Gene Name\": \"CYP2D6\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf\", \"Content to Search\": \"Plasma concentration ranges or AUC data for sertraline in CYP2D6 ultrarapid metabolizers.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the effect of DPYD poor metabolizer status on fluorouracil (the active metabolite of capecitabine) clearance?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"capecitabine\", \"Gene Name\": \"DPYD\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Dihydropyrimidine Dehydrogenase Genotype and Fluoropyrimidine Dosing: 2017 Update (October 2017).pdf\", \"Content to Search\": \"Pharmacokinetic data on fluorouracil clearance in DPYD poor metabolizers after capecitabine administration\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How do NAT2 genotypes (e.g., *5, *6, *7) define slow, intermediate, and rapid acetylator phenotypes for sulfasalazine therapy?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What are the suggested plasma concentration ranges for lansoprazole in a CYP2C19 poor metabolizer?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the suggested anti-Factor Xa activity level for an apixaban-treated patient with a CYP2C9 intermediate metabolizer phenotype?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the increased risk of adverse effects for a CYP2D6 poor metabolizer taking betaxolol?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"betaxolol\", \"Gene Name\": \"CYP2D6\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf\", \"Content to Search\": \"Quantified risk data for adverse effects (e.g., bradycardia) in CYP2D6 poor metabolizers using betaxolol.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What GRK4 polymorphisms are associated with altered beta-blocker response?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"propranolol\", \"Gene Name\": \"GRK4\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf\", \"Content to Search\": \"Definitions of GRK4 polymorphisms and their functional impact on beta-blocker therapy.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What are the target plasma concentrations for mexiletine in a patient with a CYP2D6 ultrarapid metabolizer phenotype?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the suggested therapeutic range for plasma fentanyl concentrations in a CYP2D6 intermediate metabolizer?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"fentanyl\", \"Gene Name\": \"CYP2D6\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf\", \"Content to Search\": \"Plasma concentration ranges for fentanyl in CYP2D6 intermediate metabolizers.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the increased risk of adverse effects for a CYP2D6 poor metabolizer taking sertraline?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"sertraline\", \"Gene Name\": \"CYP2D6\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf\", \"Content to Search\": \"Quantified risk data for adverse effects in CYP2D6 poor metabolizers using sertraline.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the function of the CYP2C19 enzyme in the metabolism of levomilnacipran?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"levomilnacipran\", \"Gene Name\": \"CYP2C19\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf\", \"Content to Search\": \"Description of CYP2C19's role in the metabolic pathway of levomilnacipran.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What are the target therapeutic plasma concentrations for kanamycin, and how are they affected by MT-RNR1 status?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"kanamycin\", \"Gene Name\": \"MT-RNR1\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for MT-RNR1 and Aminoglycosides (May 2021).pdf\", \"Content to Search\": \"Therapeutic drug monitoring ranges for kanamycin and any specific considerations for MT-RNR1 variant carriers.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How should nevirapine dosing be adjusted for a patient who is a CYP2B6 poor metabolizer?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the recommended starting dose of mercaptopurine for a NUDT15 poor metabolizer?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"mercaptopurine\", \"Gene Name\": \"NUDT15\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium Guidelines for thiopurine dosing based on TPMT and NUDT15 genotypes: 2018 Update (November 2018).pdf\", \"Content to Search\": \"Specific dose reduction or alternative therapy recommendation for mercaptopurine in NUDT15 poor metabolizers\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the role of the CYP2C19 enzyme in the pharmacokinetics of vortioxetine?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"vortioxetine\", \"Gene Name\": \"CYP2C19\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf\", \"Content to Search\": \"Description of CYP2C19's role in vortioxetine metabolism.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How do SLCO1B1 genotypes map to repaglinide exposure phenotypes?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the function of the MATE1 transporter in the renal secretion of trimethoprim?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the recommended dose of lovastatin for a patient who is a CYP3A4 poor metabolizer?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the recommended fluoxetine dose for a CYP2C19 poor metabolizer?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"fluoxetine\", \"Gene Name\": \"CYP2C19\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf\", \"Content to Search\": \"Dose adjustment protocol for fluoxetine in CYP2C19 poor metabolizers.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the dosing recommendation for tadalafil for pulmonary hypertension in patients with known CYP3A4 variants?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the function of the SLC6A4 gene product in the mechanism of action of fluoxetine?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"fluoxetine\", \"Gene Name\": \"SLC6A4\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf\", \"Content to Search\": \"Explanation of SLC6A4's role as the serotonin transporter, the primary target of fluoxetine.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What are the expected pharmacodynamic effects (e.g., change in heart rate) in a patient with a GRK5 polymorphism taking bisoprolol?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"bisoprolol\", \"Gene Name\": \"GRK5\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf\", \"Content to Search\": \"Pharmacodynamic data for bisoprolol stratified by GRK5 genotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the role of the CACNA1S gene in the mechanism of halothane-triggered malignant hyperthermia?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"halothane\", \"Gene Name\": \"CACNA1S\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for the use of potent volatile anesthetic agents and succinylcholine in the context of RYR1 or CACNA1S genotypes.pdf\", \"Content to Search\": \"Explanation of the CACNA1S gene function and its role in the pathophysiology of halothane-induced malignant hyperthermia.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the function of the CYP2D6 enzyme in the hydroxylation of clomipramine?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"clomipramine\", \"Gene Name\": \"CYP2D6\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium Guideline (CPICÂ®) for CYP2D6 and CYP2C19 Genotypes and Dosing of Tricyclic Antidepressants: 2016 Update (December 2016).pdf\", \"Content to Search\": \"Role of CYP2D6 in the metabolic pathway of clomipramine\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What GRK5 polymorphisms are associated with altered beta-blocker response in heart failure?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"nebivolol\", \"Gene Name\": \"GRK5\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf\", \"Content to Search\": \"Definitions of GRK5 polymorphisms (e.g., Gln41Leu) and their functional impact on beta-blocker therapy.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the function of the paraoxonase 1 enzyme (PON1) in the metabolism of clopidogrel?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the increased risk of oral hypoesthesia with asenapine in individuals who are CYP1A2 poor metabolizers?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the dosing recommendation for acebutolol in patients with hypertension and a GRK4 polymorphism associated with altered response?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"acebutolol\", \"Gene Name\": \"GRK4\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf\", \"Content to Search\": \"Dosing guidelines for acebutolol in hypertensive patients, adjusted for GRK4 genotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "Which CYP2C19 diplotypes define a poor metabolizer for the purpose of proguanil therapy?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the increased risk of SAMS for a CYP3A4 poor metabolizer taking pravastatin?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"pravastatin\", \"Gene Name\": \"CYP3A4\", \"CPIC Guideline Name\": \"The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf\", \"Content to Search\": \"Quantified risk data for SAMS in CYP3A4 poor metabolizers using pravastatin.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the risk of SAMS for an individual with an HMGCR variant associated with reduced statin response when taking pitavastatin?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"pitavastatin\", \"Gene Name\": \"HMGCR\", \"CPIC Guideline Name\": \"The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf\", \"Content to Search\": \"Quantified risk data for SAMS in individuals with HMGCR variants taking pitavastatin.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the function of the CYP2D6 enzyme in the metabolism of tramadol?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"tramadol\", \"Gene Name\": \"CYP2D6\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf\", \"Content to Search\": \"Description of CYP2D6's role in converting tramadol to its active metabolite, O-desmethyltramadol.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the dosing recommendation for sotalol in patients of African ancestry with hypertension and a high-activity GRK4 variant?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"sotalol\", \"Gene Name\": \"GRK4\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf\", \"Content to Search\": \"Dosing guidelines for sotalol in patients of African ancestry, adjusted for GRK4 genotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the recommended methotrexate dose for a patient with the MTHFR 677TT genotype?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What are the expected hematological changes, such as hemoglobin drop, in a G6PD deficient individual exposed to high-dose aspirin?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"aspirin\", \"Gene Name\": \"G6PD\", \"CPIC Guideline Name\": \"Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf\", \"Content to Search\": \"Data on hematological parameters in G6PD deficient individuals after high-dose aspirin administration.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What are the expected plasma concentrations of citalopram in a CYP2C19 poor metabolizer?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"citalopram\", \"Gene Name\": \"CYP2C19\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf\", \"Content to Search\": \"Plasma concentration ranges or AUC data for citalopram in CYP2C19 poor metabolizers.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the increased risk of peripheral neuropathy with paclitaxel in patients with the ABCB1 G2677T/A polymorphism?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "Which CYP3A4 genotypes are classified as intermediate metabolizers in the context of eszopiclone treatment?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How should montelukast dosing be adjusted for a patient with a SLCO1B1 low-function genotype?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What are the target plasma concentrations for trabectedin in a patient with a CYP3A4 rapid metabolizer phenotype?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What are the target serum urate levels for a febuxostat-treated patient based on their ABCG2 genotype?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "Which TPMT diplotypes define a normal metabolizer for the purpose of ibuprofen therapy?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How does the CYP2D6 enzyme contribute to the bioactivation of tamoxifen?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"tamoxifen\", \"Gene Name\": \"CYP2D6\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and Tamoxifen Therapy (January 2018).pdf\", \"Content to Search\": \"Mechanism of tamoxifen's metabolic activation to endoxifen by CYP2D6\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the mechanism by which mepacrine causes oxidative stress leading to hemolysis in G6PD deficient individuals?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"mepacrine\", \"Gene Name\": \"G6PD\", \"CPIC Guideline Name\": \"Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf\", \"Content to Search\": \"Biochemical mechanism of mepacrine-induced oxidative damage to red blood cells in the context of G6PD deficiency.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the increased risk of SAMS for an individual with SLCO1B1 low function taking rosuvastatin?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"rosuvastatin\", \"Gene Name\": \"SLCO1B1\", \"CPIC Guideline Name\": \"The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf\", \"Content to Search\": \"Quantified risk or odds ratio for SAMS in individuals with SLCO1B1 low function taking rosuvastatin.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the dosing recommendation for esmolol in pediatric patients with the ADRB1 Arg389Gly polymorphism?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"esmolol\", \"Gene Name\": \"ADRB1\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf\", \"Content to Search\": \"Pediatric dosing guidelines for esmolol adjusted for ADRB1 genotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What diplotypes define a CYP2C19 intermediate metabolizer?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"escitalopram\", \"Gene Name\": \"CYP2C19\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf\", \"Content to Search\": \"Diplotype definitions and activity scores for the CYP2C19 intermediate metabolizer phenotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the dosing recommendation for paromomycin in a pediatric patient with a pathogenic MT-RNR1 variant?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"paromomycin\", \"Gene Name\": \"MT-RNR1\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for MT-RNR1 and Aminoglycosides (May 2021).pdf\", \"Content to Search\": \"Specific dosing guidance for paromomycin in pediatric populations carrying pathogenic MT-RNR1 variants.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What are the target plasma concentrations for metronidazole in a patient with a CYP2C9 intermediate metabolizer phenotype?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the allopurinol dosing recommendation for a patient with chronic kidney disease who is also an HLA-B*58:01 carrier?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"allopurinol\", \"Gene Name\": \"HLA-B\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for Human Leukocyte Antigen-B (HLA-B) Genotype and Allopurinol Dosing (February 2013).pdf\", \"Content to Search\": \"Dosing recommendations for allopurinol in patients with both chronic kidney disease and HLA-B*58:01 positive status\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the increased risk of bradycardia and myalgia with alectinib in individuals with reduced CYP3A4 function?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What G6PD genotypes are classified as deficient (e.g., Class I, II, or III variants)?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"primaquine\", \"Gene Name\": \"G6PD\", \"CPIC Guideline Name\": \"Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf\", \"Content to Search\": \"Definitions of G6PD genotypes and their classification into different functional/phenotypic classes of deficiency.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "Which populations have a higher prevalence of the HLA-B*15:02 allele, impacting carbamazepine prescribing?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"carbamazepine\", \"Gene Name\": \"HLA-B\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for HLA Genotype and Use of Carbamazepine and Oxcarbazepine: 2017 Update (December 2017).pdf\", \"Content to Search\": \"Definition of populations with high HLA-B*15:02 allele frequency\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the dosing recommendation for gliclazide in a diabetic patient with G6PD deficiency?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"gliclazide\", \"Gene Name\": \"G6PD\", \"CPIC Guideline Name\": \"Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf\", \"Content to Search\": \"Dosing guidelines for gliclazide in G6PD deficient patients with type 2 diabetes.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "Should the dose of peginterferon alfa-2b be altered for a patient with the IFNL4-ÎG/TT genotype?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"peginterferon alfa-2b\", \"Gene Name\": \"IFNL4\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for IFNL3 (IL28B) Genotype and PEG interferon-alpha-based Regimens (February 2014).pdf\", \"Content to Search\": \"Dose adjustment protocol for peginterferon alfa-2b based on IFNL4 genotype\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the increased risk of Cushing's syndrome with oral budesonide in individuals with severely reduced CYP3A4 function?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How should losartan dosing be adjusted for a patient with a specific variant in the AGTR1 gene?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the function of the CYP2D6 enzyme in the metabolism of buprenorphine?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"buprenorphine\", \"Gene Name\": \"CYP2D6\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf\", \"Content to Search\": \"Description of CYP2D6's role in buprenorphine metabolism.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the increased risk of hepatotoxicity with isoniazid in individuals who are NAT2 slow acetylators?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the recommended dexlansoprazole dose for a CYP2C19 poor metabolizer?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"dexlansoprazole\", \"Gene Name\": \"CYP2C19\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C19 and Proton Pump Inhibitor Dosing (August 2020).pdf\", \"Content to Search\": \"Dose adjustment protocol for dexlansoprazole in CYP2C19 poor metabolizers.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the function of the CYP1A2 enzyme in the N-demethylation of altretamine?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the role of CYP3A4 in the N-demethylation of codeine to norcodeine?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the dosing recommendation for oxycodone in pediatric patients with a COMT high-activity genotype?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"oxycodone\", \"Gene Name\": \"COMT\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf\", \"Content to Search\": \"Pediatric dosing guidelines for oxycodone adjusted for COMT high-activity genotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the expected increase in tenoxicam exposure (AUC) in a CYP2C9 poor metabolizer?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"tenoxicam\", \"Gene Name\": \"CYP2C9\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf\", \"Content to Search\": \"Pharmacokinetic data on tenoxicam exposure in CYP2C9 poor metabolizers.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How should labetalol dosing be adjusted for an individual with a GRK4 polymorphism associated with altered response?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"labetalol\", \"Gene Name\": \"GRK4\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf\", \"Content to Search\": \"Dose adjustment protocol for labetalol based on GRK4 genotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the suggested target for serum urate reduction in a probenecid-treated patient based on their OAT1 genotype?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the function of DNA gyrase and topoisomerase IV, and how do their genetic alterations confer resistance to levofloxacin?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the function of the GRK4 enzyme in the context of nadolol therapy?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"nadolol\", \"Gene Name\": \"GRK4\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf\", \"Content to Search\": \"Explanation of GRK4's role in desensitizing adrenergic receptors and its influence on nadolol efficacy.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the dosing recommendation for cytarabine in pediatric AML patients based on their CDA genotype?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What diplotypes define a CYP3A4 intermediate metabolizer for armodafinil therapy?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What are the expected plasma lovastatin concentrations in an individual with ABCG2 decreased function?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"lovastatin\", \"Gene Name\": \"ABCG2\", \"CPIC Guideline Name\": \"The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf\", \"Content to Search\": \"Plasma concentration ranges or AUC data for lovastatin in individuals with ABCG2 decreased function.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What diplotypes define a CYP3A4 intermediate metabolizer for tadalafil therapy?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What G6PD genotypes are classified as deficient (e.g., Class I, II, or III variants)?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"moxifloxacin\", \"Gene Name\": \"G6PD\", \"CPIC Guideline Name\": \"Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf\", \"Content to Search\": \"Definitions of G6PD genotypes and their classification into different functional/phenotypic classes of deficiency.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the increased risk of proarrhythmic effects with flecainide in patients with reduced CYP2D6 function?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How do CSF3R genotypes correlate with G-CSF response phenotypes in congenital neutropenia?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the function of the ADRB1 receptor in the mechanism of action of labetalol?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"labetalol\", \"Gene Name\": \"ADRB1\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf\", \"Content to Search\": \"Explanation of ADRB1's role as the beta-1 adrenergic receptor, a primary target for labetalol.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the dosing recommendation for milnacipran in a pediatric patient with a CYP2D6 poor metabolizer phenotype?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"milnacipran\", \"Gene Name\": \"CYP2D6\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf\", \"Content to Search\": \"Pediatric dosing adjustments for milnacipran in CYP2D6 poor metabolizers.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the function of the CYP2C9 enzyme in the metabolism of pitavastatin?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"pitavastatin\", \"Gene Name\": \"CYP2C9\", \"CPIC Guideline Name\": \"The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf\", \"Content to Search\": \"Description of CYP2C9's role in pitavastatin metabolism.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What are the expected pharmacodynamic effects (e.g., change in blood pressure) in a patient with a GRK4 polymorphism taking esmolol?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"esmolol\", \"Gene Name\": \"GRK4\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf\", \"Content to Search\": \"Pharmacodynamic data for esmolol stratified by GRK4 genotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the suggested therapeutic range for plasma montelukast in a patient with a specific CYP2C8 diplotype?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How do CYP3A4 genotypes map to buspirone clearance phenotypes?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the increased risk of SAMS for an individual with SLCO1B1 low function taking lovastatin?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"lovastatin\", \"Gene Name\": \"SLCO1B1\", \"CPIC Guideline Name\": \"The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf\", \"Content to Search\": \"Quantified risk or odds ratio for SAMS in individuals with SLCO1B1 low function taking lovastatin.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the suggested therapeutic range for plasma fluticasone concentrations in a CYP3A4 rapid metabolizer?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What are the expected plasma pravastatin concentrations in a CYP3A5 normal metabolizer (expresser)?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"pravastatin\", \"Gene Name\": \"CYP3A5\", \"CPIC Guideline Name\": \"The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf\", \"Content to Search\": \"Plasma concentration ranges or AUC data for pravastatin in CYP3A5 normal metabolizers.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What diplotypes define a CYP3A4 intermediate metabolizer for olaparib therapy?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What G6PD genotypes are classified as deficient (e.g., Class I, II, or III variants)?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"furazolidone\", \"Gene Name\": \"G6PD\", \"CPIC Guideline Name\": \"Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf\", \"Content to Search\": \"Definitions of G6PD genotypes and their classification into different functional/phenotypic classes of deficiency.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the quantified risk of ototoxicity when administering amikacin to a patient with a pathogenic MT-RNR1 variant?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"amikacin\", \"Gene Name\": \"MT-RNR1\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for MT-RNR1 and Aminoglycosides (May 2021).pdf\", \"Content to Search\": \"Incidence rates or risk multipliers for amikacin-induced ototoxicity in MT-RNR1 variant carriers.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How should denosumab dosing be adjusted for a patient with a specific variant in the RANKL (TNFSF11) gene?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the quantified risk of reduced blood pressure response for an individual with a high-activity GRK4 variant when taking pindolol?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"pindolol\", \"Gene Name\": \"GRK4\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf\", \"Content to Search\": \"Risk multipliers or clinical data on reduced efficacy of pindolol in patients with high-activity GRK4 variants.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How should quinidine dosing be adjusted for a patient who is a CYP2D6 poor metabolizer?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the suggested therapeutic range for plasma piperacillin concentrations in a patient with a high-function OAT genotype?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What are the expected pharmacodynamic effects (e.g., change in heart rate) in a patient with a GRK5 polymorphism taking esmolol?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"esmolol\", \"Gene Name\": \"GRK5\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf\", \"Content to Search\": \"Pharmacodynamic data for esmolol stratified by GRK5 genotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the quantified risk of acute hemolytic anemia for a G6PD deficient individual taking rasburicase?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"rasburicase\", \"Gene Name\": \"G6PD\", \"CPIC Guideline Name\": \"Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf\", \"Content to Search\": \"Incidence rates or risk multipliers for acute hemolytic anemia with rasburicase use in G6PD deficient patients.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How do RANKL genotypes correlate with denosumab efficacy phenotypes in osteoporosis?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the role of the COMT enzyme in the pharmacological response to buprenorphine?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"buprenorphine\", \"Gene Name\": \"COMT\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf\", \"Content to Search\": \"Mechanism of interaction between COMT enzyme activity and buprenorphine's effects.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the suggested therapeutic range for plasma albendazole sulfoxide (active metabolite) in a CYP3A4 rapid metabolizer?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How does MGMT promoter methylation status correlate with lomustine efficacy and toxicity phenotypes?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How do CYP3A4 genotypes map to alectinib clearance and toxicity phenotypes?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the increased risk of adverse effects for a CYP2D6 poor metabolizer taking carvedilol?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"carvedilol\", \"Gene Name\": \"CYP2D6\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf\", \"Content to Search\": \"Quantified risk data for adverse effects (e.g., bradycardia) in CYP2D6 poor metabolizers using carvedilol.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the increased risk of severe diarrhea and neutropenia with topotecan in individuals with the ABCG2 Q141K variant?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What diplotypes define a CYP3A4 intermediate metabolizer for lenvatinib therapy?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the function of the ADRB1 receptor in the mechanism of action of acebutolol?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"acebutolol\", \"Gene Name\": \"ADRB1\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf\", \"Content to Search\": \"Explanation of ADRB1's role as the beta-1 adrenergic receptor, a primary target for acebutolol.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the role of the COMT enzyme in the pharmacological response to sufentanil?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"sufentanil\", \"Gene Name\": \"COMT\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf\", \"Content to Search\": \"Mechanism of interaction between COMT enzyme activity and sufentanil's effects.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the role of the UGT1A1 enzyme in the metabolism of atazanavir?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"atazanavir\", \"Gene Name\": \"UGT1A1\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for UGT1A1 and Atazanavir Prescribing (September 2015).pdf\", \"Content to Search\": \"Mechanism of UGT1A1-mediated atazanavir metabolism and its role in bilirubin conjugation.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the recommended paroxetine dose for a CYP2D6 poor metabolizer?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"paroxetine\", \"Gene Name\": \"CYP2D6\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf\", \"Content to Search\": \"Dose adjustment protocol for paroxetine in CYP2D6 poor metabolizers.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What are the target plasma concentrations for repaglinide in a patient with a high-function SLCO1B1 genotype?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How should labetalol dosing be adjusted for an individual with ADRB2 polymorphisms like Gly16Arg or Gln27Glu?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"labetalol\", \"Gene Name\": \"ADRB2\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf\", \"Content to Search\": \"Dose adjustment protocol for labetalol based on ADRB2 genotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the recommended dose of levetiracetam for a patient with a SV2A gene polymorphism?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the basic mechanism of linezolid's weak, reversible inhibition of Monoamine Oxidase A?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the recommended paroxetine dose for a CYP2B6 poor metabolizer?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"paroxetine\", \"Gene Name\": \"CYP2B6\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf\", \"Content to Search\": \"Dose adjustment protocol for paroxetine in CYP2B6 poor metabolizers.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the increased risk of severe constipation with solifenacin in patients with reduced CYP3A4 function?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the recommended nadolol dose for a CYP2D6 poor metabolizer?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"nadolol\", \"Gene Name\": \"CYP2D6\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf\", \"Content to Search\": \"Dose adjustment protocol for nadolol in CYP2D6 poor metabolizers.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How does the CYP2C8*3 allele affect the pharmacokinetics of tenoxicam?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"tenoxicam\", \"Gene Name\": \"CYP2C8\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf\", \"Content to Search\": \"Pharmacokinetic data on tenoxicam exposure related to the CYP2C8*3 allele.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the probability of achieving sustained virologic response (SVR) with peginterferon alfa-2a in a patient with an unfavorable IFNL3 genotype?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"peginterferon alfa-2a\", \"Gene Name\": \"IFNL3\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for IFNL3 (IL28B) Genotype and PEG interferon-alpha-based Regimens (February 2014).pdf\", \"Content to Search\": \"Quantified SVR rates for peginterferon alfa-2a therapy in patients with unfavorable IFNL3 genotypes\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What are the target plasma concentrations for nateglinide in a patient with a CYP2C9 rapid metabolizer phenotype?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the expected clinical response (pharmacodynamics) for a patient with the SLC6A4 l/s genotype taking vortioxetine?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"vortioxetine\", \"Gene Name\": \"SLC6A4\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf\", \"Content to Search\": \"Pharmacodynamic data (e.g., remission rates) for vortioxetine based on SLC6A4 5-HTTLPR genotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What are the expected plasma concentrations of escitalopram in a CYP2D6 ultrarapid metabolizer?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"escitalopram\", \"Gene Name\": \"CYP2D6\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf\", \"Content to Search\": \"Plasma concentration ranges or AUC data for escitalopram in CYP2D6 ultrarapid metabolizers.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "Which CYP3A4 genotypes are classified as poor metabolizers in the context of sufentanil treatment?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the dosing recommendation for methotrexate in pediatric oncology patients based on their MTHFR genotype?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the suggested therapeutic range for plasma montelukast concentrations in a patient with a high-function SLCO1B1 genotype?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What are the suggested plasma concentration limits for linezolid to avoid hematologic toxicity based on MAOA genotype?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the target level of bone turnover marker suppression for a denosumab-treated patient based on their RANKL genotype?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How do CYP2C8 genotypes map to paclitaxel clearance phenotypes?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What are the expected plasma carvedilol concentrations in a CYP2D6 ultrarapid metabolizer?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"carvedilol\", \"Gene Name\": \"CYP2D6\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf\", \"Content to Search\": \"Plasma concentration ranges or AUC data for carvedilol in CYP2D6 ultrarapid metabolizers.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the recommended dosing for streptomycin in an individual with a pathogenic MT-RNR1 variant?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"streptomycin\", \"Gene Name\": \"MT-RNR1\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for MT-RNR1 and Aminoglycosides (May 2021).pdf\", \"Content to Search\": \"Dosing recommendations or alternative therapies for streptomycin in patients with pathogenic MT-RNR1 variants.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the dosing recommendation for salmeterol/fluticasone combination therapy in pediatric patients with the ADRB2 Gly16Gly genotype?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the recommended dose of prasugrel for a patient with a specific variant in the PON1 gene?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the risk of poor response to fluoxetine for individuals with the HTR2A rs7997012 A allele?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"fluoxetine\", \"Gene Name\": \"HTR2A\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf\", \"Content to Search\": \"Quantified risk or clinical evidence for altered fluoxetine efficacy in patients with the HTR2A rs7997012 A allele.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the recommended dosing for succinylcholine in a patient with a RYR1 genotype conferring Malignant Hyperthermia Susceptibility?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"succinylcholine\", \"Gene Name\": \"RYR1\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for the use of potent volatile anesthetic agents and succinylcholine in the context of RYR1 or CACNA1S genotypes.pdf\", \"Content to Search\": \"Dosing protocol or avoidance recommendation for succinylcholine in patients with RYR1-Malignant Hyperthermia Susceptibility.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the recommended atorvastatin dose for an individual with SLCO1B1 low function?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"atorvastatin\", \"Gene Name\": \"SLCO1B1\", \"CPIC Guideline Name\": \"The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf\", \"Content to Search\": \"Dose adjustment protocol for atorvastatin in individuals with SLCO1B1 low function.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the function of the CYP2C8 enzyme in the metabolic pathway of the ALK inhibitor brigatinib?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the mechanism by which MT-RNR1 variants increase susceptibility to plazomicin-induced ototoxicity?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"plazomicin\", \"Gene Name\": \"MT-RNR1\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for MT-RNR1 and Aminoglycosides (May 2021).pdf\", \"Content to Search\": \"Functional explanation of how MT-RNR1 variants interact with plazomicin to cause cellular damage.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What genotypes of the HTR2A gene (e.g., rs6313) are associated with altered paroxetine response?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"paroxetine\", \"Gene Name\": \"HTR2A\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf\", \"Content to Search\": \"Definitions of HTR2A genotypes and their association with paroxetine efficacy.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the function of the calcium-sensing receptor (CASR) in calcium homeostasis and its relevance to calcium supplementation?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What diplotypes define a CYP2C19 ultrarapid metabolizer?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"milnacipran\", \"Gene Name\": \"CYP2C19\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf\", \"Content to Search\": \"Diplotype definitions and activity scores for the CYP2C19 ultrarapid metabolizer phenotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How does the ABCB1 genotype correspond to P-glycoprotein expression and citalopram response phenotypes?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What are the target serum dihydrotestosterone (DHT) suppression levels for a dutasteride-treated patient based on their SRD5A2 genotype?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How does the PON1 genotype correspond to prasugrel bioactivation phenotypes?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the function of the CYP4F2 enzyme in relation to vitamin K metabolism?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"warfarin\", \"Gene Name\": \"CYP4F2\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for Pharmacogenetics-guided Warfarin Dosing: 2016 Update.pdf\", \"Content to Search\": \"Role of the CYP4F2 enzyme in the vitamin K cycle\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What OPRM1 variants are associated with altered hydromorphone response?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"hydromorphone\", \"Gene Name\": \"OPRM1\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf\", \"Content to Search\": \"List and description of OPRM1 variants and their corresponding functional impact on hydromorphone response.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How should abemaciclib dosing be adjusted for a patient who is a CYP3A4 poor metabolizer?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the suggested therapeutic range for plasma trimethoprim concentrations in a patient with a high-function MATE1 genotype?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the function of the MATE1 transporter in the renal secretion of famotidine?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the recommended dose of clarithromycin for a patient who is a CYP3A4 poor metabolizer?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the increased risk of dyspnea with ticagrelor in patients with reduced CYP3A4 function?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the increased risk of breast cancer recurrence for a CYP2D6 intermediate metabolizer on tamoxifen therapy?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"tamoxifen\", \"Gene Name\": \"CYP2D6\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and Tamoxifen Therapy (January 2018).pdf\", \"Content to Search\": \"Quantified risk of disease recurrence for CYP2D6 intermediate metabolizers taking tamoxifen\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the increased risk of severe neuropathy with paclitaxel in individuals with CYP2C8*3 alleles?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the dosing recommendation for atorvastatin in pediatric patients with a CYP2C9 poor metabolizer phenotype?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"atorvastatin\", \"Gene Name\": \"CYP2C9\", \"CPIC Guideline Name\": \"The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf\", \"Content to Search\": \"Pediatric dosing adjustments for atorvastatin in CYP2C9 poor metabolizers.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What are the target plasma concentrations for doxycycline in a patient with a CYP3A4 rapid metabolizer phenotype?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the function of the GRK4 gene product in the context of acebutolol therapy?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"acebutolol\", \"Gene Name\": \"GRK4\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf\", \"Content to Search\": \"Explanation of the role of G protein-coupled receptor kinase 4 in adrenergic receptor desensitization.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the mechanism by which MT-RNR1 variants increase susceptibility to paromomycin-induced ototoxicity?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"paromomycin\", \"Gene Name\": \"MT-RNR1\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for MT-RNR1 and Aminoglycosides (May 2021).pdf\", \"Content to Search\": \"Functional explanation of how MT-RNR1 variants interact with paromomycin to cause cellular damage.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How do SLC22A2 genotypes map to gabapentin clearance phenotypes?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "Is norfloxacin contraindicated or should dosing be adjusted for a G6PD deficient individual?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"norfloxacin\", \"Gene Name\": \"G6PD\", \"CPIC Guideline Name\": \"Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf\", \"Content to Search\": \"Dosing protocol or contraindication for norfloxacin in G6PD deficient individuals.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the recommended propranolol dose for an individual with a GRK4 variant associated with altered response?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"propranolol\", \"Gene Name\": \"GRK4\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf\", \"Content to Search\": \"Dose adjustment protocol for propranolol based on GRK4 genotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How does NUDT15 deficiency impact the ratio of 6-TGN to 6-MMPN metabolites during mercaptopurine therapy?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"mercaptopurine\", \"Gene Name\": \"NUDT15\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium Guidelines for thiopurine dosing based on TPMT and NUDT15 genotypes: 2018 Update (November 2018).pdf\", \"Content to Search\": \"Pharmacokinetic data on the ratio of active to inactive metabolites in NUDT15 deficient individuals on mercaptopurine\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the recommended dosing for tobramycin in an individual with a pathogenic MT-RNR1 variant?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"tobramycin\", \"Gene Name\": \"MT-RNR1\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for MT-RNR1 and Aminoglycosides (May 2021).pdf\", \"Content to Search\": \"Dosing recommendations or alternative therapies for tobramycin in patients with pathogenic MT-RNR1 variants.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the increased risk of nephrotoxicity with high-dose intravenous acyclovir in individuals with low-function OAT1 transporter variants?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the azathioprine dosing recommendation for a patient who is a TPMT intermediate metabolizer AND a NUDT15 intermediate metabolizer?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"azathioprine\", \"Gene Name\": \"TPMT\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium Guidelines for thiopurine dosing based on TPMT and NUDT15 genotypes: 2018 Update (November 2018).pdf\", \"Content to Search\": \"Dosing guidance for azathioprine in patients with combined TPMT and NUDT15 intermediate metabolizer status\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What diplotypes define a CYP2D6 ultrarapid metabolizer?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"labetalol\", \"Gene Name\": \"CYP2D6\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf\", \"Content to Search\": \"Diplotype definitions and activity scores for the CYP2D6 ultrarapid metabolizer phenotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the quantified risk of acute hemolytic anemia for a G6PD deficient individual taking probenecid?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"probenecid\", \"Gene Name\": \"G6PD\", \"CPIC Guideline Name\": \"Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf\", \"Content to Search\": \"Incidence rates or risk multipliers for acute hemolytic anemia with probenecid use in G6PD deficient patients.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How should fluvoxamine dosing be adjusted for an individual with the HTR2A rs7997012 A/A genotype?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"fluvoxamine\", \"Gene Name\": \"HTR2A\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf\", \"Content to Search\": \"Dosing or therapeutic recommendations for fluvoxamine based on HTR2A rs7997012 genotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the dosing recommendation for methadone for opioid use disorder in patients with a CYP2B6*6 allele?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the function of the CYP2C9 enzyme in the metabolic inactivation of torsemide?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the recommended starting dose of pantoprazole for a patient who is a CYP2C19 poor metabolizer?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the function of the SLC6A4 gene product in the mechanism of action of sertraline?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"sertraline\", \"Gene Name\": \"SLC6A4\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf\", \"Content to Search\": \"Description of the serotonin transporter's (SERT) role as the primary target of sertraline.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the risk of SAMS for an individual with an HMGCR variant associated with reduced statin response when taking rosuvastatin?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"rosuvastatin\", \"Gene Name\": \"HMGCR\", \"CPIC Guideline Name\": \"The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf\", \"Content to Search\": \"Quantified risk data for SAMS in individuals with HMGCR variants taking rosuvastatin.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the increased risk of myelosuppression with lenalidomide in individuals with specific CRBN variants?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the recommended metoprolol dose for an individual with the ADRB1 Arg389Gly polymorphism (Gly/Gly genotype)?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"metoprolol\", \"Gene Name\": \"ADRB1\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf\", \"Content to Search\": \"Dose adjustment protocol for metoprolol based on ADRB1 Arg389Gly genotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the increased risk of hepatotoxicity from acetaminophen in individuals with low-activity UGT1A6 variants?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the function of P-glycoprotein (ABCB1) in the absorption and clearance of edoxaban?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the function of the CYP2D6*4 allele in relation to drug metabolism?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"tropisetron\", \"Gene Name\": \"CYP2D6\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 Genotype and Use of Ondansetron and Tropisetron (December 2016).pdf\", \"Content to Search\": \"Functional description of the non-functional CYP2D6*4 allele\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How do CYP3A4 genotypes correlate with fingolimod phosphorylation and clearance phenotypes?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What diplotypes define a CYP2D6 ultrarapid metabolizer?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"vortioxetine\", \"Gene Name\": \"CYP2D6\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf\", \"Content to Search\": \"Diplotype definitions and activity scores for the CYP2D6 ultrarapid metabolizer phenotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the function of the UGT1A9 enzyme in the primary metabolic pathway of propofol?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What GRK5 polymorphisms are associated with altered beta-blocker response?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"atenolol\", \"Gene Name\": \"GRK5\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf\", \"Content to Search\": \"Definitions of GRK5 variants (e.g., Gln41Leu) and their association with beta-blocker efficacy.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the mechanism by which nalidixic acid causes oxidative stress leading to hemolysis in G6PD deficient individuals?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"nalidixic acid\", \"Gene Name\": \"G6PD\", \"CPIC Guideline Name\": \"Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf\", \"Content to Search\": \"Biochemical mechanism of nalidixic acid-induced oxidative damage to red blood cells in the context of G6PD deficiency.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the increased risk of severe cutaneous adverse reactions (SCARs) for an HLA-B*58:01 carrier taking allopurinol?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"allopurinol\", \"Gene Name\": \"HLA-B\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for Human Leukocyte Antigen-B (HLA-B) Genotype and Allopurinol Dosing (February 2013).pdf\", \"Content to Search\": \"Quantified risk or odds ratio for SCARs in HLA-B*58:01 carriers taking allopurinol\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the increased risk of hypokalemia with HCTZ in individuals with specific variants in the adducin 1 (ADD1) gene?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the function of the SULT1A1 enzyme in the metabolism of tamoxifen's active metabolites?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What are the expected plasma fluvastatin concentrations in a CYP3A5 normal metabolizer (expresser)?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"fluvastatin\", \"Gene Name\": \"CYP3A5\", \"CPIC Guideline Name\": \"The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf\", \"Content to Search\": \"Plasma concentration ranges or AUC data for fluvastatin in CYP3A5 normal metabolizers.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the role of the COMT enzyme in the pharmacological response to hydrocodone?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"hydrocodone\", \"Gene Name\": \"COMT\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf\", \"Content to Search\": \"Mechanism of interaction between COMT enzyme activity and hydrocodone's effects.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What are the target serum dihydrotestosterone (DHT) suppression levels for a finasteride-treated patient based on their SRD5A2 genotype?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the risk of SAMS for an individual with an HMGCR variant associated with reduced statin response when taking pravastatin?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"pravastatin\", \"Gene Name\": \"HMGCR\", \"CPIC Guideline Name\": \"The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf\", \"Content to Search\": \"Quantified risk data for SAMS in individuals with HMGCR variants taking pravastatin.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How do ABCB1 genotypes correlate with omeprazole efficacy phenotypes in treating GERD?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the target level of CYP3A4 inhibition for a patient treated with ketoconazole, based on their own CYP3A4 genotype?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the increased risk of adverse effects from guaifenesin in individuals with genetic polymorphisms in hypothetical metabolizing enzymes?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the increased risk of retinopathy with long-term chloroquine use in CYP2D6 poor metabolizers?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the function of the CYP2D6 enzyme in the metabolism of oxycodone?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"oxycodone\", \"Gene Name\": \"CYP2D6\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf\", \"Content to Search\": \"Description of CYP2D6's role in converting oxycodone to its active metabolite, oxymorphone.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What MT-RNR1 variants define a high-risk phenotype for aminoglycoside-induced hearing loss?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"kanamycin\", \"Gene Name\": \"MT-RNR1\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for MT-RNR1 and Aminoglycosides (May 2021).pdf\", \"Content to Search\": \"List of specific MT-RNR1 variants or diplotypes associated with increased risk of ototoxicity.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the risk of inadequate analgesia for individuals with the OPRM1 A118G variant when taking hydromorphone?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"hydromorphone\", \"Gene Name\": \"OPRM1\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf\", \"Content to Search\": \"Quantified risk or clinical evidence for reduced analgesic efficacy of hydromorphone in patients with the OPRM1 A118G variant.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What are the expected hematological changes in a G6PD deficient individual exposed to sulfanilamide?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"sulfanilamide\", \"Gene Name\": \"G6PD\", \"CPIC Guideline Name\": \"Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf\", \"Content to Search\": \"Data on hematological parameters in G6PD deficient individuals after sulfanilamide administration.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What HMGCR variants are associated with altered statin response?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"atorvastatin\", \"Gene Name\": \"HMGCR\", \"CPIC Guideline Name\": \"The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf\", \"Content to Search\": \"Definitions of HMGCR variants or genotypes associated with altered statin efficacy.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "Are there any special considerations for pediatric patients on desipramine with a known CYP2C19 variant?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"desipramine\", \"Gene Name\": \"CYP2C19\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium Guideline (CPICÂ®) for CYP2D6 and CYP2C19 Genotypes and Dosing of Tricyclic Antidepressants: 2016 Update (December 2016).pdf\", \"Content to Search\": \"Pediatric dosing or safety considerations for desipramine related to CYP2C19 status\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the function of the vitamin D receptor (VDR) in mediating the genomic effects of calcitriol?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What are the expected plasma propranolol concentrations in a CYP2D6 ultrarapid metabolizer?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"propranolol\", \"Gene Name\": \"CYP2D6\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf\", \"Content to Search\": \"Plasma concentration ranges or AUC data for propranolol in CYP2D6 ultrarapid metabolizers.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the expected plasma concentration of doxepin in a CYP2C19 ultrarapid metabolizer?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"doxepin\", \"Gene Name\": \"CYP2C19\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium Guideline (CPICÂ®) for CYP2D6 and CYP2C19 Genotypes and Dosing of Tricyclic Antidepressants: 2016 Update (December 2016).pdf\", \"Content to Search\": \"Pharmacokinetic data on doxepin plasma concentrations in CYP2C19 ultrarapid metabolizers\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the increased risk of poor blood pressure control with losartan in individuals with the AGTR1 1166A>C polymorphism?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the suggested therapeutic range for plasma omeprazole concentrations in a CYP3A4 rapid metabolizer?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the function of the CYP2D6 enzyme in the metabolic clearance of diphenhydramine?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How should trastuzumab dosing be adjusted for a patient with a specific FCGR2A (Fc gamma receptor IIa) H131R polymorphism?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the risk of SJS/TEN when using oxcarbazepine in an HLA-B*15:02 positive patient?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"oxcarbazepine\", \"Gene Name\": \"HLA-B\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for HLA Genotype and Use of Carbamazepine and Oxcarbazepine: 2017 Update (December 2017).pdf\", \"Content to Search\": \"Quantified risk of SJS/TEN for oxcarbazepine use in HLA-B*15:02 carriers\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the function of the HTR2A gene product in the mechanism of action of paroxetine?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"paroxetine\", \"Gene Name\": \"HTR2A\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf\", \"Content to Search\": \"Description of the 5-HT2A receptor's role in antidepressant response and as a potential pharmacodynamic factor for paroxetine.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the role of the CYP2C9 enzyme in the metabolism of aceclofenac?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"aceclofenac\", \"Gene Name\": \"CYP2C9\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf\", \"Content to Search\": \"Description of CYP2C9's function in aceclofenac's metabolic pathway.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the function of the OATP1B1 transporter (encoded by SLCO1B1) in the hepatic uptake of valsartan?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the function of the CYP2B6*6 allele in the context of bupropion metabolism?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How do CYP2D6 genotypes correlate with propafenone efficacy and safety phenotypes?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the dosing recommendation for duloxetine in adolescents with the HTR2A rs7997012 A/A genotype?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"duloxetine\", \"Gene Name\": \"HTR2A\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf\", \"Content to Search\": \"Dosing guidelines for duloxetine in adolescent patients, adjusted for HTR2A genotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the quantified risk of acute hemolytic anemia for a G6PD deficient individual taking primaquine?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"primaquine\", \"Gene Name\": \"G6PD\", \"CPIC Guideline Name\": \"Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf\", \"Content to Search\": \"Incidence rates or risk multipliers for acute hemolytic anemia with primaquine use in G6PD deficient patients.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the quantified risk of altered therapeutic response for an individual with the ADRB2 Gly16Arg polymorphism taking carvedilol?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"carvedilol\", \"Gene Name\": \"ADRB2\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf\", \"Content to Search\": \"Quantified risk data for altered efficacy in individuals with the ADRB2 Gly16Arg polymorphism taking carvedilol.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the increased risk of excessive sedation with alprazolam in patients with reduced CYP3A4 function?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the recommended atorvastatin dose for an individual with an HMGCR variant associated with reduced statin response?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"atorvastatin\", \"Gene Name\": \"HMGCR\", \"CPIC Guideline Name\": \"The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf\", \"Content to Search\": \"Dose adjustment protocol for atorvastatin based on HMGCR genotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How do NQO1 genotypes correlate with mitomycin C bioactivation and efficacy phenotypes?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the dosing recommendation for pitavastatin in pediatric patients with a CYP3A4 poor metabolizer phenotype?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"pitavastatin\", \"Gene Name\": \"CYP3A4\", \"CPIC Guideline Name\": \"The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf\", \"Content to Search\": \"Pediatric dosing adjustments for pitavastatin in CYP3A4 poor metabolizers.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What are the target plasma concentrations for ivermectin in a patient with a high-activity ABCB1 genotype?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the increased risk of adverse effects for a CYP2C19 poor metabolizer taking fluvoxamine?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"fluvoxamine\", \"Gene Name\": \"CYP2C19\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf\", \"Content to Search\": \"Quantified risk data for adverse effects in CYP2C19 poor metabolizers using fluvoxamine.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the suggested therapeutic range for plasma sildenafil concentrations in a CYP3A4 rapid metabolizer?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the increased risk of severe hypotension with clonidine in individuals who are CYP2D6 poor metabolizers?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the quantified risk of Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN) in an HLA-B*15:02 positive individual taking carbamazepine?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"carbamazepine\", \"Gene Name\": \"HLA-B\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for HLA Genotype and Use of Carbamazepine and Oxcarbazepine: 2017 Update (December 2017).pdf\", \"Content to Search\": \"Risk multiplier or incidence rate of SJS/TEN in HLA-B*15:02 carriers taking carbamazepine\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How should betaxolol dosing be adjusted for an individual with an ADRA2C polymorphism associated with altered response?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"betaxolol\", \"Gene Name\": \"ADRA2C\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf\", \"Content to Search\": \"Dose adjustment protocol for betaxolol based on ADRA2C genotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the risk of altered therapeutic effect for individuals with the OPRM1 A118G variant when taking naltrexone?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"naltrexone\", \"Gene Name\": \"OPRM1\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf\", \"Content to Search\": \"Quantified risk or clinical evidence for altered therapeutic efficacy of naltrexone in patients with the OPRM1 A118G variant.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the dosing recommendation for hydrocodone in breastfeeding mothers who are CYP2D6 ultrarapid metabolizers?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"hydrocodone\", \"Gene Name\": \"CYP2D6\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf\", \"Content to Search\": \"Dosing recommendations or contraindications for hydrocodone in lactating mothers with a CYP2D6 UM phenotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the suggested therapeutic range for plasma larotrectinib concentrations in a CYP3A4 rapid metabolizer?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the increased risk of myopathy with atorvastatin when co-administered with a strong CYP3A4 inhibitor in a patient with already reduced CYP3A4 function?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the immunological mechanism by which the HLA-B*57:01 allele leads to abacavir hypersensitivity?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"abacavir\", \"Gene Name\": \"HLA-B\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium Guidelines for HLA-B Genotype and Abacavir Dosing (April 2012).pdf\", \"Content to Search\": \"Description of the immunological mechanism involving HLA-B*57:01 and abacavir\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the increased risk of SAMS for a CYP3A5 normal metabolizer (expresser) taking rosuvastatin?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"rosuvastatin\", \"Gene Name\": \"CYP3A5\", \"CPIC Guideline Name\": \"The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf\", \"Content to Search\": \"Quantified risk data for SAMS in CYP3A5 normal metabolizers using rosuvastatin.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What diplotypes define a CYP2D6 intermediate metabolizer for risperidone therapy according to CPIC?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the suggested target hemoglobin level for an EPO-treated patient with chronic kidney disease, based on their EPOR genotype?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the function of the OATP1B1 transporter in the hepatic uptake of gemfibrozil?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How should ganciclovir dosing be adjusted for a patient with a specific organic anion transporter (OAT1/SLC22A6) variant?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How should fluoxetine dosing be adjusted for an individual with the HTR2A rs7997012 A/A genotype?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"fluoxetine\", \"Gene Name\": \"HTR2A\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf\", \"Content to Search\": \"Dosing or therapeutic recommendations for fluoxetine based on HTR2A rs7997012 genotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the function of the GRK4 enzyme in the context of sotalol therapy?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"sotalol\", \"Gene Name\": \"GRK4\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf\", \"Content to Search\": \"Explanation of GRK4's role in desensitizing adrenergic receptors and its influence on sotalol efficacy.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What are the expected plasma metoprolol concentrations in a CYP2D6 ultrarapid metabolizer?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"metoprolol\", \"Gene Name\": \"CYP2D6\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf\", \"Content to Search\": \"Plasma concentration ranges or AUC data for metoprolol in CYP2D6 ultrarapid metabolizers.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the dosing recommendation for oxycodone in breastfeeding mothers who are CYP2D6 ultrarapid metabolizers?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"oxycodone\", \"Gene Name\": \"CYP2D6\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf\", \"Content to Search\": \"Dosing recommendations or contraindications for oxycodone in lactating mothers with a CYP2D6 UM phenotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the recommended initial dose of naproxen for a patient with a CYP2C9 poor metabolizer phenotype?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"naproxen\", \"Gene Name\": \"CYP2C9\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf\", \"Content to Search\": \"Dose adjustment protocol for naproxen in CYP2C9 poor metabolizers.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "Which CYP3A4 genotypes are classified as poor metabolizers in the context of nifedipine treatment?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "Is there an increased risk of gastrointestinal bleeding with ibuprofen in patients carrying TPMT deficiency alleles?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the dosing recommendation for aminosalicylic acid in a pediatric patient with G6PD deficiency?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"aminosalicylic acid\", \"Gene Name\": \"G6PD\", \"CPIC Guideline Name\": \"Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf\", \"Content to Search\": \"Pediatric-specific dosing guidelines or contraindications for aminosalicylic acid in G6PD deficient children.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the role of the RYR1 gene in the mechanism of enflurane-triggered malignant hyperthermia?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"enflurane\", \"Gene Name\": \"RYR1\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for the use of potent volatile anesthetic agents and succinylcholine in the context of RYR1 or CACNA1S genotypes.pdf\", \"Content to Search\": \"Explanation of the RYR1 gene function and its role in the pathophysiology of enflurane-induced malignant hyperthermia.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the recommended vortioxetine dose for a CYP2B6 poor metabolizer?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"vortioxetine\", \"Gene Name\": \"CYP2B6\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf\", \"Content to Search\": \"Dose adjustment protocol for vortioxetine in CYP2B6 poor metabolizers.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What are the expected hematological changes in a G6PD deficient individual exposed to chloroquine?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"chloroquine\", \"Gene Name\": \"G6PD\", \"CPIC Guideline Name\": \"Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf\", \"Content to Search\": \"Data on hematological parameters in G6PD deficient individuals after chloroquine administration.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the increased risk of visual disturbances with vardenafil in patients with reduced CYP3A4 function?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the function of the CYP2C9 enzyme in the minor metabolic pathway of apixaban?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the function of the CYP2D6 enzyme in the metabolism of alfentanil?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"alfentanil\", \"Gene Name\": \"CYP2D6\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf\", \"Content to Search\": \"Description of CYP2D6's role in alfentanil metabolism.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the increased risk of adverse effects with telmisartan in individuals with reduced UGT1A1 function?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the dosing recommendation for betaxolol in pediatric patients with the ADRB1 Arg389Gly polymorphism?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"betaxolol\", \"Gene Name\": \"ADRB1\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf\", \"Content to Search\": \"Pediatric dosing guidelines for betaxolol adjusted for ADRB1 genotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the suggested therapeutic range for plasma nevirapine concentrations in a CYP2B6 intermediate metabolizer?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the function of the CYP2B6*6 allele in efavirenz metabolism?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"efavirenz\", \"Gene Name\": \"CYP2B6\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2B6 and Efavirenz-containing Antiretroviral Therapy (April 2019).pdf\", \"Content to Search\": \"Description of the CYP2B6*6 allele's impact on enzyme function and efavirenz metabolism.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What are the expected pharmacodynamic effects (e.g., change in heart rate or blood pressure) in a patient with the ADRA2C Ins/Del polymorphism taking atenolol?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"atenolol\", \"Gene Name\": \"ADRA2C\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf\", \"Content to Search\": \"Pharmacodynamic data (heart rate, blood pressure response) for atenolol stratified by ADRA2C genotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How do CYP2A6 genotypes map to efavirenz metabolism phenotypes?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "In which pediatric populations is HLA-B*15:02 screening recommended before initiating fosphenytoin therapy?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"fosphenytoin\", \"Gene Name\": \"HLA-B\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for CYP2C9 and HLA-B Genotype and Phenytoin Dosing (August 2020).pdf\", \"Content to Search\": \"Recommendations for HLA-B*15:02 screening in specific pediatric or ethnic populations before fosphenytoin use\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the risk of poor response to dupilumab for atopic dermatitis in individuals with IL4R variants that affect signaling?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the dosing recommendation for morphine in pediatric patients with a COMT low-activity genotype?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"morphine\", \"Gene Name\": \"COMT\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf\", \"Content to Search\": \"Pediatric dosing guidelines for morphine adjusted for COMT low-activity genotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the increased risk of musculoskeletal side effects with letrozole in individuals with reduced CYP2A6 function?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the dosing recommendation for extended-release oxybutynin in elderly patients with known CYP3A4 variants?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What are the expected pharmacodynamic effects (e.g., change in heart rate) in a patient with a GRK5 polymorphism taking atenolol?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"atenolol\", \"Gene Name\": \"GRK5\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf\", \"Content to Search\": \"Pharmacodynamic data for atenolol stratified by GRK5 genotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What are the target plasma concentrations for alectinib and its active metabolite M4 in a patient with a CYP3A4 rapid metabolizer phenotype?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What are the target plasma concentrations for empagliflozin in a patient with a low-activity UGT2B7 genotype?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the quantified risk of altered therapeutic response for an individual with the ADRB2 Gln27Glu polymorphism when taking pindolol?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"pindolol\", \"Gene Name\": \"ADRB2\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf\", \"Content to Search\": \"Risk multipliers or clinical data on the efficacy of pindolol in patients with the ADRB2 Gln27Glu polymorphism.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How do SLC22A6/SLC22A8 genotypes correlate with piperacillin clearance phenotypes?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How does CYP2C19 polymorphism affect the first-pass metabolism of rabeprazole?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"rabeprazole\", \"Gene Name\": \"CYP2C19\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C19 and Proton Pump Inhibitor Dosing (August 2020).pdf\", \"Content to Search\": \"Description of CYP2C19's role in rabeprazole's mechanism and metabolism.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the recommended initial phenytoin dose for a CYP2C9 poor metabolizer?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"phenytoin\", \"Gene Name\": \"CYP2C9\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for CYP2C9 and HLA-B Genotype and Phenytoin Dosing (August 2020).pdf\", \"Content to Search\": \"Initial dose and adjustment protocol for phenytoin in CYP2C9 poor metabolizers\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What are the target plasma concentrations for vismodegib in a patient with a CYP2C9 intermediate metabolizer phenotype?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the function of the CYP3A4 enzyme in the 3-hydroxylation of quinine?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the risk of opioid overdose for a CYP2B6 poor metabolizer on a standard methadone dose?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"methadone\", \"Gene Name\": \"CYP2B6\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium Guideline for CYP2B6 Genotype and Methadone Therapy (July 2024).pdf\", \"Content to Search\": \"Quantified risk data for toxicity or overdose in CYP2B6 poor metabolizers using methadone.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the risk of aspirin resistance in individuals with specific PTGS1 variants?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the increased risk of failed therapy for a CYP2C19 ultrarapid metabolizer taking a standard dose of escitalopram?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"escitalopram\", \"Gene Name\": \"CYP2C19\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf\", \"Content to Search\": \"Quantified risk data for lack of efficacy in CYP2C19 ultrarapid metabolizers using escitalopram.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What are the expected pharmacodynamic effects (e.g., heart rate reduction) in a patient with the ADRB1 Arg389Arg genotype taking bisoprolol?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"bisoprolol\", \"Gene Name\": \"ADRB1\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf\", \"Content to Search\": \"Pharmacodynamic data (heart rate, blood pressure response) for bisoprolol stratified by ADRB1 genotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How should paroxetine dosing be adjusted for an individual with the HTR2A rs6313 G/G genotype?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"paroxetine\", \"Gene Name\": \"HTR2A\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf\", \"Content to Search\": \"Dose adjustment protocol for paroxetine based on HTR2A rs6313 genotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the dosing recommendation for olaparib in ovarian cancer patients with known CYP3A4 variants?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "Are there specific PK/PD parameters to monitor for succinylcholine in a patient with CACNA1S-related Malignant Hyperthermia Susceptibility?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"succinylcholine\", \"Gene Name\": \"CACNA1S\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for the use of potent volatile anesthetic agents and succinylcholine in the context of RYR1 or CACNA1S genotypes.pdf\", \"Content to Search\": \"Pharmacokinetic or pharmacodynamic monitoring parameters for succinylcholine in the context of CACNA1S-MHS.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How should buprenorphine dosing be adjusted for an individual with an OPRM1 variant associated with decreased receptor function (e.g., A118G)?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"buprenorphine\", \"Gene Name\": \"OPRM1\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf\", \"Content to Search\": \"Dose adjustment protocol for buprenorphine based on OPRM1 variants affecting receptor function.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How do KCNH2 genotypes map to dofetilide risk-stratification phenotypes?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What diplotypes for CYP1A2 define a poor metabolizer in the context of ramelteon therapy?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the recommended dose of etoposide for a patient with a low-function ABCB1 genotype?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the increased risk of adverse effects for a CYP2B6 poor metabolizer taking milnacipran?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"milnacipran\", \"Gene Name\": \"CYP2B6\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf\", \"Content to Search\": \"Quantified risk data for adverse effects in CYP2B6 poor metabolizers using milnacipran.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the dosing recommendation for escitalopram in pediatric patients with a CYP2D6 poor metabolizer phenotype?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"escitalopram\", \"Gene Name\": \"CYP2D6\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf\", \"Content to Search\": \"Pediatric dosing adjustments for escitalopram in CYP2D6 poor metabolizers.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the thioguanine dosing recommendation for a patient with IBD who is a TPMT poor metabolizer?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"thioguanine\", \"Gene Name\": \"TPMT\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium Guidelines for thiopurine dosing based on TPMT and NUDT15 genotypes: 2018 Update (November 2018).pdf\", \"Content to Search\": \"Dosing guidance or contraindication for thioguanine in IBD patients with TPMT poor metabolizer status\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "Are there specific recommendations for ibuprofen use in pediatric patients who are also CYP2C9 poor metabolizers?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"ibuprofen\", \"Gene Name\": \"CYP2C9\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf\", \"Content to Search\": \"Dosing guidance for ibuprofen in pediatric CYP2C9 poor metabolizers.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the suggested therapeutic range for plasma hydromorphone concentrations in a patient with an OPRM1 variant leading to increased receptor expression?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"hydromorphone\", \"Gene Name\": \"OPRM1\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf\", \"Content to Search\": \"Therapeutic drug monitoring values for hydromorphone stratified by OPRM1 genotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the increased risk of osteonecrosis of the jaw with denosumab in individuals with specific RANKL variants?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the recommended dosing for enflurane in a patient with a CACNA1S genotype conferring Malignant Hyperthermia Susceptibility?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"enflurane\", \"Gene Name\": \"CACNA1S\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for the use of potent volatile anesthetic agents and succinylcholine in the context of RYR1 or CACNA1S genotypes.pdf\", \"Content to Search\": \"Dosing protocol or avoidance recommendation for enflurane in patients with CACNA1S-Malignant Hyperthermia Susceptibility.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What are the expected plasma vortioxetine concentrations in a CYP2D6 ultrarapid metabolizer?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"vortioxetine\", \"Gene Name\": \"CYP2D6\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf\", \"Content to Search\": \"Plasma concentration ranges or AUC data for vortioxetine in CYP2D6 ultrarapid metabolizers.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How do CYP3A4 genotypes map to ponatinib clearance and toxicity phenotypes?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What are the expected hematological changes in a G6PD deficient individual exposed to ofloxacin?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"ofloxacin\", \"Gene Name\": \"G6PD\", \"CPIC Guideline Name\": \"Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf\", \"Content to Search\": \"Data on hematological parameters in G6PD deficient individuals after ofloxacin administration.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How should sertraline dosing be modified for patients with the OPRM1 A118G variant?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the increased risk of flushing with dimethyl fumarate in individuals with specific HCAR2 variants?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the function of the GRK5 enzyme in the context of propranolol therapy?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"propranolol\", \"Gene Name\": \"GRK5\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf\", \"Content to Search\": \"Explanation of GRK5's role in desensitizing adrenergic receptors and its influence on propranolol efficacy.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the dosing recommendation for paroxetine in a pediatric patient with a CYP2D6 poor metabolizer phenotype?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"paroxetine\", \"Gene Name\": \"CYP2D6\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf\", \"Content to Search\": \"Pediatric dosing adjustments for paroxetine in CYP2D6 poor metabolizers.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the increased risk of developing a severe cutaneous adverse reaction (SCAR) to allopurinol in individuals with the ABCG2 421C>A polymorphism?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the suggested therapeutic range for plasma canrenone (spironolactone's active metabolite) in a CYP3A4 rapid metabolizer?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "Is there an increased risk of adverse events with celecoxib in patients with reduced-function CYP2C8 alleles?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"celecoxib\", \"Gene Name\": \"CYP2C8\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf\", \"Content to Search\": \"Quantified risk data for adverse events in patients with reduced-function CYP2C8 alleles using celecoxib.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the mechanism by which tolbutamide causes oxidative stress leading to hemolysis in G6PD deficient individuals?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"tolbutamide\", \"Gene Name\": \"G6PD\", \"CPIC Guideline Name\": \"Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf\", \"Content to Search\": \"Biochemical mechanism of tolbutamide-induced oxidative damage to red blood cells in the context of G6PD deficiency.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the dosing recommendation for atenolol in patients with hypertension and a GRK4 polymorphism associated with altered response?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"atenolol\", \"Gene Name\": \"GRK4\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf\", \"Content to Search\": \"Dosing guidelines for atenolol in hypertensive patients, adjusted for GRK4 genotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the expected clinical response to desvenlafaxine in a patient with the HTR2A rs7997012 G/G genotype?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"desvenlafaxine\", \"Gene Name\": \"HTR2A\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf\", \"Content to Search\": \"Pharmacodynamic data, such as remission rates, for desvenlafaxine stratified by HTR2A rs7997012 genotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How should oxybutynin dosing be adjusted for a patient who is a CYP3A4 poor metabolizer?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How should fondaparinux dosing be adjusted for a patient with a specific antithrombin (SERPINC1) gene variant?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How should atenolol dosing be adjusted for an individual with ADRB2 polymorphisms like Gly16Arg or Gln27Glu?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"atenolol\", \"Gene Name\": \"ADRB2\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf\", \"Content to Search\": \"Dose adjustment protocol for atenolol based on ADRB2 genotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the increased risk of severe skin toxicity with erlotinib in patients with reduced CYP1A2 function?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What are the target plasma concentrations for clonidine in a patient with a CYP2D6 ultrarapid metabolizer phenotype?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How should larotrectinib dosing be adjusted for a patient who is a CYP3A4 poor metabolizer?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the increased risk of adverse effects for a CYP2D6 poor metabolizer taking milnacipran?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"milnacipran\", \"Gene Name\": \"CYP2D6\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf\", \"Content to Search\": \"Quantified risk data for adverse effects in CYP2D6 poor metabolizers using milnacipran.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the function of the NUDT15 enzyme in the metabolic pathway of azathioprine?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"azathioprine\", \"Gene Name\": \"NUDT15\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium Guidelines for thiopurine dosing based on TPMT and NUDT15 genotypes: 2018 Update (November 2018).pdf\", \"Content to Search\": \"Role of the NUDT15 enzyme in deactivating thiopurine metabolites\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the suggested therapeutic range for plasma irbesartan concentrations in a CYP2C9 intermediate metabolizer?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the role of the Carbonic Anhydrase II enzyme in the mechanism of action and side effect profile of topiramate?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the quantified risk of aminoglycoside-induced deafness for tobramycin users with the MT-RNR1 m.1555A>G variant?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the function of P-glycoprotein (ABCB1) in limiting the CNS penetration of ivermectin?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the increased risk of tumor lysis syndrome (TLS) with venetoclax in individuals with reduced CYP3A4 function?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the increased risk of adverse effects for a CYP2D6 poor metabolizer taking vilazodone?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"vilazodone\", \"Gene Name\": \"CYP2D6\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf\", \"Content to Search\": \"Quantified risk data for adverse effects in CYP2D6 poor metabolizers using vilazodone.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How do SLCO1B1 genotypes correlate with rifampin-induced liver injury phenotypes?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the increased risk of Torsades de Pointes with moxifloxacin in individuals with congenital long QT syndrome?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the function of the CYP3A4 enzyme in the metabolism of fluvastatin?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"fluvastatin\", \"Gene Name\": \"CYP3A4\", \"CPIC Guideline Name\": \"The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf\", \"Content to Search\": \"Description of CYP3A4's role in fluvastatin metabolism.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the recommended dosing adjustment for tegafur in patients with a DPYD poor metabolizer phenotype?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"tegafur\", \"Gene Name\": \"DPYD\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Dihydropyrimidine Dehydrogenase Genotype and Fluoropyrimidine Dosing: 2017 Update (October 2017).pdf\", \"Content to Search\": \"Dose adjustment protocol for tegafur in DPYD poor metabolizers\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "Are there specific clomipramine dosing guidelines for adolescents with OCD who are CYP2C19 ultrarapid metabolizers?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"clomipramine\", \"Gene Name\": \"CYP2C19\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium Guideline (CPICÂ®) for CYP2D6 and CYP2C19 Genotypes and Dosing of Tricyclic Antidepressants: 2016 Update (December 2016).pdf\", \"Content to Search\": \"Adolescent dosing recommendations for clomipramine in CYP2C19 ultrarapid metabolizers\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How should armodafinil dosing be adjusted for a patient who is a CYP3A4 poor metabolizer?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the dosing recommendation for ramelteon in patients who are heavy smokers (CYP1A2 inducers)?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How do AGTR1 genotypes correlate with candesartan efficacy phenotypes?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "Are there specific PK/PD parameters to monitor for sevoflurane in a patient with CACNA1S-related Malignant Hyperthermia Susceptibility?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"sevoflurane\", \"Gene Name\": \"CACNA1S\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for the use of potent volatile anesthetic agents and succinylcholine in the context of RYR1 or CACNA1S genotypes.pdf\", \"Content to Search\": \"Pharmacokinetic or pharmacodynamic monitoring parameters for sevoflurane in the context of CACNA1S-MHS.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the increased risk of non-infectious leukocytosis and differentiation syndrome with enasidenib in individuals with reduced UGT1A1 function?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the quantified risk of reduced blood pressure response for an individual with the ADRB1 Arg389Arg genotype when taking sotalol?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"sotalol\", \"Gene Name\": \"ADRB1\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf\", \"Content to Search\": \"Risk multipliers or clinical data on the efficacy of sotalol in patients with the ADRB1 Arg389Arg genotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the risk of treatment failure with standard lansoprazole dosing for a CYP2C19 ultrarapid metabolizer?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"lansoprazole\", \"Gene Name\": \"CYP2C19\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C19 and Proton Pump Inhibitor Dosing (August 2020).pdf\", \"Content to Search\": \"Quantified risk data for therapeutic failure in CYP2C19 ultrarapid metabolizers using lansoprazole.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What ADRA2C polymorphisms are associated with altered beta-blocker response?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"esmolol\", \"Gene Name\": \"ADRA2C\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf\", \"Content to Search\": \"Definitions of ADRA2C variants (e.g., Ins/Del) and their association with beta-blocker efficacy.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the expected clinical response (pharmacodynamics) for a patient with the SLC6A4 l/s genotype taking paroxetine?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"paroxetine\", \"Gene Name\": \"SLC6A4\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf\", \"Content to Search\": \"Pharmacodynamic data (e.g., remission rates) for paroxetine based on SLC6A4 5-HTTLPR genotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How do host KCNH2 genotypes correlate with moxifloxacin-induced cardiotoxicity phenotypes?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the basic mechanism by which a KRAS mutation leads to constitutive activation of the EGFR pathway, rendering cetuximab ineffective?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the recommended initial dose of celecoxib for a patient with a CYP2C9 poor metabolizer phenotype?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"celecoxib\", \"Gene Name\": \"CYP2C9\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf\", \"Content to Search\": \"Dose adjustment protocol for celecoxib in CYP2C9 poor metabolizers.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the function of the ABCG2 transporter in the pharmacokinetics of lovastatin?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"lovastatin\", \"Gene Name\": \"ABCG2\", \"CPIC Guideline Name\": \"The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf\", \"Content to Search\": \"Description of ABCG2's role as an efflux transporter affecting lovastatin disposition.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How should zaleplon dosing be adjusted for a patient with a specific aldehyde oxidase (AOX1) gene variant?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the increased risk of adverse effects with sitagliptin in individuals with low-function OAT3 transporter variants?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the recommended dose of ropinirole for a patient who is a CYP1A2 poor metabolizer?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the increased risk of dizziness and serotonin syndrome with buspirone in individuals with reduced CYP3A4 function?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the function of the CYP2D6 enzyme in the metabolic pathway of rosuvastatin?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the risk of cardiotoxicity for a CYP2D6 poor metabolizer taking amitriptyline?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"amitriptyline\", \"Gene Name\": \"CYP2D6\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium Guideline (CPICÂ®) for CYP2D6 and CYP2C19 Genotypes and Dosing of Tricyclic Antidepressants: 2016 Update (December 2016).pdf\", \"Content to Search\": \"Quantified risk of cardiotoxicity or QTc prolongation in CYP2D6 poor metabolizers on amitriptyline\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the suggested therapeutic range for plasma hydromorphone concentrations in a CYP2D6 intermediate metabolizer?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"hydromorphone\", \"Gene Name\": \"CYP2D6\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf\", \"Content to Search\": \"Plasma concentration ranges for hydromorphone in CYP2D6 intermediate metabolizers.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the increased risk of severe anticholinergic effects (e.g., delirium) with diphenhydramine in elderly patients who are CYP2D6 poor metabolizers?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the contribution of CYP2C8 to the overall clearance of meloxicam?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"meloxicam\", \"Gene Name\": \"CYP2C8\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf\", \"Content to Search\": \"Description of CYP2C8's role in meloxicam's metabolic pathway.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the function of the CYP3A4 enzyme in the metabolism of the R-enantiomer of modafinil (armodafinil)?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the suggested therapeutic range for plasma topotecan concentrations in a patient with a high-activity ABCG2 genotype?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the risk of oxcarbazepine-induced cutaneous adverse reactions in individuals with the HLA-A*31:01 allele?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"oxcarbazepine\", \"Gene Name\": \"HLA-A\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for HLA Genotype and Use of Carbamazepine and Oxcarbazepine: 2017 Update (December 2017).pdf\", \"Content to Search\": \"Quantified risk data for cutaneous adverse reactions with oxcarbazepine in HLA-A*31:01 carriers\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How should buprenorphine dosing be adjusted for a CYP2D6 poor metabolizer?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"buprenorphine\", \"Gene Name\": \"CYP2D6\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf\", \"Content to Search\": \"Dose adjustment protocol for buprenorphine in CYP2D6 poor metabolizers.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the recommended dose of benazepril for a patient with a specific variant in the ACE gene?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the recommended starting dose of ramipril for a patient with the ACE DD genotype?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the suggested therapeutic range for plasma vardenafil concentrations in a CYP3A4 rapid metabolizer?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the recommended nebivolol dose for an individual with the GRK5 Gln41Leu polymorphism?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"nebivolol\", \"Gene Name\": \"GRK5\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf\", \"Content to Search\": \"Dose adjustment protocol for nebivolol based on GRK5 Gln41Leu genotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the risk of inadequate analgesia for individuals with the OPRM1 A118G variant when taking methadone?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"methadone\", \"Gene Name\": \"OPRM1\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf\", \"Content to Search\": \"Quantified risk or clinical evidence for reduced analgesic efficacy of methadone in patients with the OPRM1 A118G variant.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How do VDR genotypes (e.g., FokI, BsmI, TaqI) correlate with calcitriol efficacy and safety phenotypes?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the function of the CYP1A2 enzyme in the metabolism of the dopamine agonist ropinirole?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What are the target plasma concentrations for budesonide in an inhaled formulation for a patient with a CYP3A4 rapid metabolizer phenotype?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the increased risk of hepatotoxicity with ketoconazole in individuals with pre-existing CYP3A4 variants?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How do CYP3A4 genotypes map to trabectedin clearance phenotypes?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the function of the CYP1A2*1F allele in the context of clozapine metabolism and its interaction with smoking?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the role of the CYP3A5 enzyme in tacrolimus metabolism?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"tacrolimus\", \"Gene Name\": \"CYP3A5\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for CYP3A5 genotype and Tacrolimus Dosing (July 2015).pdf\", \"Content to Search\": \"Function of CYP3A5 enzyme in the metabolic pathway of tacrolimus\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the increased risk of adverse effects for a CYP2D6 poor metabolizer taking vortioxetine?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"vortioxetine\", \"Gene Name\": \"CYP2D6\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf\", \"Content to Search\": \"Quantified risk data for adverse effects in CYP2D6 poor metabolizers using vortioxetine.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the quantified risk of malignant hyperthermia when administering succinylcholine to a patient with a pathogenic RYR1 variant?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"succinylcholine\", \"Gene Name\": \"RYR1\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for the use of potent volatile anesthetic agents and succinylcholine in the context of RYR1 or CACNA1S genotypes.pdf\", \"Content to Search\": \"Incidence rates or risk data for succinylcholine-triggered malignant hyperthermia in patients with pathogenic RYR1 variants.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How does the CYP2C8*3 allele affect the pharmacokinetics of lornoxicam?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"lornoxicam\", \"Gene Name\": \"CYP2C8\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf\", \"Content to Search\": \"Pharmacokinetic data on lornoxicam exposure related to the CYP2C8*3 allele.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the increased risk of salicylate toxicity with bismuth subsalicylate in individuals with UGT1A6 poor metabolizer status?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What diplotypes define a CYP2D6 ultrarapid metabolizer?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"desvenlafaxine\", \"Gene Name\": \"CYP2D6\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf\", \"Content to Search\": \"Diplotype definitions and activity scores for the CYP2D6 ultrarapid metabolizer phenotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the recommended vilazodone dose for a CYP2D6 poor metabolizer?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"vilazodone\", \"Gene Name\": \"CYP2D6\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf\", \"Content to Search\": \"Dose adjustment protocol for vilazodone in CYP2D6 poor metabolizers.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the dosing recommendation for sufentanil in pediatric patients with a COMT high-activity genotype?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"sufentanil\", \"Gene Name\": \"COMT\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf\", \"Content to Search\": \"Pediatric dosing guidelines for sufentanil adjusted for COMT high-activity genotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What diplotypes for CYP1A2 indicate a need for caffeine consumption counseling during clozapine therapy?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the recommended pitavastatin dose for a CYP3A4 poor metabolizer?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"pitavastatin\", \"Gene Name\": \"CYP3A4\", \"CPIC Guideline Name\": \"The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf\", \"Content to Search\": \"Dose adjustment protocol for pitavastatin in CYP3A4 poor metabolizers.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the recommended initial dose of lornoxicam for a patient with a CYP2C9 poor metabolizer phenotype?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"lornoxicam\", \"Gene Name\": \"CYP2C9\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf\", \"Content to Search\": \"Dose adjustment protocol for lornoxicam in CYP2C9 poor metabolizers.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the increased risk of SAMS for a CYP3A5 normal metabolizer (expresser) taking atorvastatin?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"atorvastatin\", \"Gene Name\": \"CYP3A5\", \"CPIC Guideline Name\": \"The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf\", \"Content to Search\": \"Quantified risk data for SAMS in CYP3A5 normal metabolizers using atorvastatin.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the dosing recommendation for rosuvastatin in pediatric patients with an HMGCR variant associated with reduced statin response?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"rosuvastatin\", \"Gene Name\": \"HMGCR\", \"CPIC Guideline Name\": \"The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf\", \"Content to Search\": \"Pediatric dosing adjustments for rosuvastatin based on HMGCR genotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the recommended dose of febuxostat for a patient with a specific variant in the ABCG2 gene?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What G6PD genotypes are classified as deficient (e.g., Class I, II, or III variants)?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"aminosalicylic acid\", \"Gene Name\": \"G6PD\", \"CPIC Guideline Name\": \"Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf\", \"Content to Search\": \"Definitions of G6PD genotypes and their classification into different functional/phenotypic classes of deficiency.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the recommended dose of linezolid for a patient with a genetic predisposition to myelosuppression?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How should betaxolol dosing be adjusted for an individual with a GRK5 polymorphism associated with altered response?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"betaxolol\", \"Gene Name\": \"GRK5\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf\", \"Content to Search\": \"Dose adjustment protocol for betaxolol based on GRK5 genotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the role of the mu-opioid receptor (encoded by OPRM1) in the antidepressant mechanism of sertraline?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the increased risk of central respiratory depression with morphine in individuals with ABCB1 variants that reduce efflux from the brain?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the increased risk of thrombosis with erythropoietin in individuals with specific EPOR gain-of-function mutations?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What are the expected pharmacodynamic effects (e.g., heart rate reduction) in a patient with the ADRA2C Ins/Del polymorphism taking metoprolol?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"metoprolol\", \"Gene Name\": \"ADRA2C\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf\", \"Content to Search\": \"Pharmacodynamic data, such as heart rate or blood pressure changes, for metoprolol stratified by ADRA2C genotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the increased risk of adverse effects for a CYP2D6 poor metabolizer taking levomilnacipran?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"levomilnacipran\", \"Gene Name\": \"CYP2D6\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf\", \"Content to Search\": \"Quantified risk data for adverse effects in CYP2D6 poor metabolizers using levomilnacipran.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the increased risk of dysgeusia with nirmatrelvir/ritonavir in patients with reduced CYP3A4 function?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What are the expected pharmacodynamic effects (e.g., heart rate reduction) in a patient with the ADRB1 Arg389Arg genotype taking atenolol?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"atenolol\", \"Gene Name\": \"ADRB1\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf\", \"Content to Search\": \"Pharmacodynamic data (heart rate, blood pressure response) for atenolol stratified by ADRB1 genotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the risk of diuretic resistance to bumetanide in individuals with specific SLC12A1 variants?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What are the expected hematological changes in a G6PD deficient individual exposed to doxorubicin?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"doxorubicin\", \"Gene Name\": \"G6PD\", \"CPIC Guideline Name\": \"Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf\", \"Content to Search\": \"Data on hematological parameters in G6PD deficient individuals after doxorubicin administration.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the increased risk of hyperbilirubinemia with lopinavir/ritonavir in individuals with the SLCO1B1 c.521T>C polymorphism?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "Are there specific guidelines for abacavir use in pediatric patients who are HLA-B*57:01 positive?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"abacavir\", \"Gene Name\": \"HLA-B\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium Guidelines for HLA-B Genotype and Abacavir Dosing (April 2012).pdf\", \"Content to Search\": \"Clinical recommendations for abacavir use in pediatric HLA-B*57:01 carriers\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "Which CYP3A4 genotypes are classified as intermediate metabolizers in the context of lurasidone treatment?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the increased risk of syncope with galantamine in patients with combined reduced function of CYP2D6 and CYP3A4?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the increased risk of adverse effects for a CYP2B6 poor metabolizer taking desvenlafaxine?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"desvenlafaxine\", \"Gene Name\": \"CYP2B6\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf\", \"Content to Search\": \"Quantified risk data for adverse effects in CYP2B6 poor metabolizers using desvenlafaxine.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the risk of treatment failure for H. pylori eradication with lansoprazole in CYP2C19 ultrarapid metabolizers?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the recommended dose of doxycycline for a patient who is a CYP3A4 poor metabolizer?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the function of the CYP3A5 enzyme in the metabolism of rosuvastatin?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"rosuvastatin\", \"Gene Name\": \"CYP3A5\", \"CPIC Guideline Name\": \"The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf\", \"Content to Search\": \"Description of CYP3A5's role in rosuvastatin metabolism.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What are the expected plasma betaxolol concentrations in a CYP2D6 ultrarapid metabolizer?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"betaxolol\", \"Gene Name\": \"CYP2D6\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf\", \"Content to Search\": \"Plasma concentration ranges or AUC data for betaxolol in CYP2D6 ultrarapid metabolizers.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the increased risk of seizures with dalfampridine in individuals with SLC22A2 variants that reduce renal clearance?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What are the expected plasma pravastatin concentrations in a CYP3A4 intermediate metabolizer?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"pravastatin\", \"Gene Name\": \"CYP3A4\", \"CPIC Guideline Name\": \"The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf\", \"Content to Search\": \"Plasma concentration ranges or AUC data for pravastatin in CYP3A4 intermediate metabolizers.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the function of the CYP3A4 enzyme in the metabolic pathway of doxycycline?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the function of the Glutamate Decarboxylase-Like 1 (GADL1) protein and its potential role in lithium's mechanism of action?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the recommended warfarin dosing algorithm for a pediatric patient with a CYP2C9 poor metabolizer phenotype?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"warfarin\", \"Gene Name\": \"CYP2C9\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for Pharmacogenetics-guided Warfarin Dosing: 2016 Update.pdf\", \"Content to Search\": \"Pediatric-specific warfarin dosing guidance for CYP2C9 poor metabolizers\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the suggested therapeutic range for plasma gliclazide concentrations in a CYP2C9 ultrarapid metabolizer?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the risk of nephrotoxicity with tacrolimus in patients with low-activity ABCB1 variants?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the increased risk of bleeding with argatroban in individuals with genetic variants causing severe hepatic impairment?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the suggested anti-Factor Xa activity level for an edoxaban-treated patient based on their ABCB1 genotype?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How does CYP2C19 polymorphism affect the first-pass metabolism of esomeprazole?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"esomeprazole\", \"Gene Name\": \"CYP2C19\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C19 and Proton Pump Inhibitor Dosing (August 2020).pdf\", \"Content to Search\": \"Description of CYP2C19's role in esomeprazole's mechanism and metabolism.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the risk of poor glycemic or weight loss response to liraglutide in individuals with low-function GLP1R variants?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the role of the RYR1 gene in the mechanism of halothane-triggered malignant hyperthermia?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"halothane\", \"Gene Name\": \"RYR1\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for the use of potent volatile anesthetic agents and succinylcholine in the context of RYR1 or CACNA1S genotypes.pdf\", \"Content to Search\": \"Explanation of the RYR1 gene function and its role in the pathophysiology of halothane-induced malignant hyperthermia.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the increased risk of thrombocytopenia and anemia with ruxolitinib in patients with reduced CYP3A4 function?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the risk of complete non-response to cetuximab in colorectal cancer patients with a KRAS mutation in codon 12 or 13?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "Is nicorandil contraindicated or should dosing be adjusted for a G6PD deficient individual?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"nicorandil\", \"Gene Name\": \"G6PD\", \"CPIC Guideline Name\": \"Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf\", \"Content to Search\": \"Dosing protocol or contraindication for nicorandil in G6PD deficient individuals.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What are the expected pharmacodynamic effects (e.g., change in blood pressure) in a patient with a GRK4 polymorphism taking betaxolol?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"betaxolol\", \"Gene Name\": \"GRK4\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf\", \"Content to Search\": \"Pharmacodynamic data for betaxolol stratified by GRK4 genotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the increased risk of severe skin reactions with bendamustine in patients with reduced CYP1A2 function?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How does the CYP2C8*3 allele affect the pharmacokinetics of diclofenac?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"diclofenac\", \"Gene Name\": \"CYP2C8\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf\", \"Content to Search\": \"Pharmacokinetic data on diclofenac exposure related to the CYP2C8*3 allele.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What are the target plasma concentrations for paclitaxel in a patient with a CYP2C8 intermediate metabolizer phenotype?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the mechanism of action of ivacaftor on the CFTR protein channel?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"ivacaftor\", \"Gene Name\": \"CFTR\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for Ivacaftor Therapy in the Context of CFTR Genotype (March 2014).pdf\", \"Content to Search\": \"Description of ivacaftor's function as a CFTR potentiator.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the recommended starting dose of azathioprine for a NUDT15 intermediate metabolizer?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"azathioprine\", \"Gene Name\": \"NUDT15\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium Guidelines for thiopurine dosing based on TPMT and NUDT15 genotypes: 2018 Update (November 2018).pdf\", \"Content to Search\": \"Dose adjustment protocol or percentage reduction for azathioprine in NUDT15 intermediate metabolizers\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the target platelet count for a romiplostim-treated patient based on their MPL genotype?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What are the expected plasma fluvastatin concentrations in a CYP3A4 intermediate metabolizer?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"fluvastatin\", \"Gene Name\": \"CYP3A4\", \"CPIC Guideline Name\": \"The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf\", \"Content to Search\": \"Plasma concentration ranges or AUC data for fluvastatin in CYP3A4 intermediate metabolizers.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the target plasma concentration range for desipramine, and how is it affected by CYP2D6 ultrarapid metabolizer status?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"desipramine\", \"Gene Name\": \"CYP2D6\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium Guideline (CPICÂ®) for CYP2D6 and CYP2C19 Genotypes and Dosing of Tricyclic Antidepressants: 2016 Update (December 2016).pdf\", \"Content to Search\": \"Therapeutic drug monitoring range for desipramine and its relation to CYP2D6 ultrarapid metabolizer status\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the contribution of CYP2C8 to the overall clearance of nabumetone?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"nabumetone\", \"Gene Name\": \"CYP2C8\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf\", \"Content to Search\": \"Description of CYP2C8's role in nabumetone's metabolic pathway.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the function of the CYP3A4 enzyme in the metabolism of pravastatin?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"pravastatin\", \"Gene Name\": \"CYP3A4\", \"CPIC Guideline Name\": \"The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf\", \"Content to Search\": \"Description of CYP3A4's role in pravastatin metabolism.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the role of CYP2C19 in the metabolism of doxepin to nordoxepin?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"doxepin\", \"Gene Name\": \"CYP2C19\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium Guideline (CPICÂ®) for CYP2D6 and CYP2C19 Genotypes and Dosing of Tricyclic Antidepressants: 2016 Update (December 2016).pdf\", \"Content to Search\": \"Function of CYP2C19 in the N-demethylation of doxepin\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What are the expected plasma concentrations of escitalopram in a CYP2B6 ultrarapid metabolizer?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"escitalopram\", \"Gene Name\": \"CYP2B6\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf\", \"Content to Search\": \"Plasma concentration ranges or AUC data for escitalopram in CYP2B6 ultrarapid metabolizers.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How do ABCB1 genotypes correlate with venlafaxine resistance phenotypes?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How should isosorbide dinitrate dosing be adjusted for a patient with a specific ALDH2 variant?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the risk of treatment failure with standard rabeprazole dosing for a CYP2C19 ultrarapid metabolizer?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"rabeprazole\", \"Gene Name\": \"CYP2C19\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C19 and Proton Pump Inhibitor Dosing (August 2020).pdf\", \"Content to Search\": \"Quantified risk data for therapeutic failure in CYP2C19 ultrarapid metabolizers using rabeprazole.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How should bisoprolol dosing be adjusted for an individual with a GRK4 polymorphism associated with altered response?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"bisoprolol\", \"Gene Name\": \"GRK4\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf\", \"Content to Search\": \"Dose adjustment protocol for bisoprolol based on GRK4 genotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How should esmolol dosing be adjusted for an individual with a GRK4 polymorphism associated with altered response?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"esmolol\", \"Gene Name\": \"GRK4\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf\", \"Content to Search\": \"Dose adjustment protocol for esmolol based on GRK4 genotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the function of the CYP2D6 enzyme in the O-demethylation of gefitinib?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the recommended dose of efavirenz for a patient with a CYP2A6 poor metabolizer phenotype?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the risk of poor blood pressure control with candesartan in individuals with the AGTR1 1166A>C polymorphism?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the recommendation for using topical sulfacetamide in a G6PD deficient patient?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"sulfacetamide\", \"Gene Name\": \"G6PD\", \"CPIC Guideline Name\": \"Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf\", \"Content to Search\": \"Guidelines for topical sulfacetamide use in G6PD deficient patients.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the risk of non-response for an individual with the SLC6A4 s/s genotype taking venlafaxine?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"venlafaxine\", \"Gene Name\": \"SLC6A4\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf\", \"Content to Search\": \"Quantified risk or odds ratio for treatment non-response in venlafaxine users with the SLC6A4 s/s genotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the increased risk of cardiovascular events (e.g., heart failure) with itraconazole in patients with reduced CYP3A4 function?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the increased risk of SAMS for a CYP2C9 poor metabolizer taking simvastatin?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"simvastatin\", \"Gene Name\": \"CYP2C9\", \"CPIC Guideline Name\": \"The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf\", \"Content to Search\": \"Quantified risk data for SAMS in CYP2C9 poor metabolizers using simvastatin.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How do PDE5A genotypes correlate with sildenafil efficacy phenotypes for erectile dysfunction?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the increased risk of adverse effects for a CYP2D6 poor metabolizer taking citalopram?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"citalopram\", \"Gene Name\": \"CYP2D6\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf\", \"Content to Search\": \"Quantified risk data for adverse effects in CYP2D6 poor metabolizers using citalopram.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the function of the CYP2B6 enzyme in the 4-hydroxylation (activation) of cyclophosphamide?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What are the plasma concentration thresholds for cisplatin ototoxicity based on COMT genotype?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the suggested QTc interval limit for a moxifloxacin-treated patient based on their KCNH2 genotype?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How do CYP3A4 genotypes map to pemigatinib clearance phenotypes?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the dosing recommendation for metoprolol in pediatric patients with hypertension and the ADRB1 Arg389Gly polymorphism?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"metoprolol\", \"Gene Name\": \"ADRB1\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf\", \"Content to Search\": \"Pediatric dosing guidelines for metoprolol adjusted for ADRB1 genotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the recommended dose of eplerenone for a patient who is a CYP3A4 poor metabolizer?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How should apixaban dosing be adjusted for a patient who is a CYP2C9 poor metabolizer?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the suggested therapeutic range for plasma rivaroxaban concentrations in a patient with a high-function SLCO1B1 genotype?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How should atenolol dosing be adjusted for an individual with a GRK5 polymorphism associated with altered response?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"atenolol\", \"Gene Name\": \"GRK5\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf\", \"Content to Search\": \"Dose adjustment protocol for atenolol based on GRK5 genotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the recommended warfarin dose adjustment for a patient who is a CYP1A2 rapid metabolizer?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the function of antithrombin, the cofactor required for fondaparinux's activity, and how do its variants cause resistance?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the dosing recommendation for aspirin in a pediatric patient with G6PD deficiency?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"aspirin\", \"Gene Name\": \"G6PD\", \"CPIC Guideline Name\": \"Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf\", \"Content to Search\": \"Pediatric-specific dosing guidelines for aspirin in G6PD deficient children, considering risks of both hemolysis and Reye's syndrome.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How do CYP3A4 genotypes map to midazolam clearance phenotypes?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What are the expected plasma atenolol concentrations in a CYP2D6 ultrarapid metabolizer?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"atenolol\", \"Gene Name\": \"CYP2D6\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf\", \"Content to Search\": \"Plasma concentration ranges or AUC data for atenolol in CYP2D6 ultrarapid metabolizers.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How should ondansetron dosing be adjusted for a patient who is a CYP1A2 poor metabolizer?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the dosing recommendation for fluoxetine in pediatric patients with a CYP2C19 poor metabolizer phenotype?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"fluoxetine\", \"Gene Name\": \"CYP2C19\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf\", \"Content to Search\": \"Pediatric dosing adjustments for fluoxetine in CYP2C19 poor metabolizers.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What are the expected hematological changes in a G6PD deficient individual exposed to dabrafenib?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"dabrafenib\", \"Gene Name\": \"G6PD\", \"CPIC Guideline Name\": \"Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf\", \"Content to Search\": \"Data on hematological parameters in G6PD deficient individuals after dabrafenib administration.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the target blood pressure reduction for a candesartan-treated patient based on their AGTR1 genotype?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How do CYP3A4 genotypes map to guanfacine clearance phenotypes?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How should daptomycin dosing be adjusted for a patient with a genetic predisposition to rhabdomyolysis?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the risk of poor response to cromolyn sodium in individuals with specific variants in mast cell signaling pathways?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What are the target plasma concentrations for buspirone in a patient with a CYP3A4 rapid metabolizer phenotype?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the clomipramine dosing recommendation for a patient who is both a CYP2D6 poor metabolizer and a CYP2C19 poor metabolizer?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"clomipramine\", \"Gene Name\": \"CYP2D6\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium Guideline (CPICÂ®) for CYP2D6 and CYP2C19 Genotypes and Dosing of Tricyclic Antidepressants: 2016 Update (December 2016).pdf\", \"Content to Search\": \"Dosing guidance for clomipramine in patients with combined CYP2D6 and CYP2C19 poor metabolizer status\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How do SLCO1B1 genotypes correlate with ceftriaxone clearance and toxicity phenotypes?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the target level of thromboxane B2 inhibition for an aspirin-treated patient based on their PTGS1 genotype?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What are the expected plasma pravastatin concentrations in a CYP2C9 intermediate metabolizer?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"pravastatin\", \"Gene Name\": \"CYP2C9\", \"CPIC Guideline Name\": \"The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf\", \"Content to Search\": \"Plasma concentration ranges or AUC data for pravastatin in CYP2C9 intermediate metabolizers.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the dosing recommendation for ribostamycin in a pediatric patient with a pathogenic MT-RNR1 variant?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"ribostamycin\", \"Gene Name\": \"MT-RNR1\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for MT-RNR1 and Aminoglycosides (May 2021).pdf\", \"Content to Search\": \"Specific dosing guidance for ribostamycin in pediatric populations carrying pathogenic MT-RNR1 variants.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the increased risk of adverse effects for a CYP2D6 ultrarapid metabolizer taking levomethadone?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"levomethadone\", \"Gene Name\": \"CYP2D6\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf\", \"Content to Search\": \"Quantified risk data for adverse effects in CYP2D6 ultrarapid metabolizers using levomethadone.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What diplotypes for CYP1A2 define a poor metabolizer in the context of erlotinib therapy?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What diplotypes define a CYP3A4 poor metabolizer?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"atorvastatin\", \"Gene Name\": \"CYP3A4\", \"CPIC Guideline Name\": \"The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf\", \"Content to Search\": \"Diplotype definitions and activity scores for the CYP3A4 poor metabolizer phenotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the dosing recommendation for simvastatin in pediatric patients with ABCG2 decreased function?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"simvastatin\", \"Gene Name\": \"ABCG2\", \"CPIC Guideline Name\": \"The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf\", \"Content to Search\": \"Pediatric dosing guidelines for simvastatin adjusted for ABCG2 decreased function.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the function of the CYP2C19 enzyme in the metabolism of citalopram?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"citalopram\", \"Gene Name\": \"CYP2C19\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf\", \"Content to Search\": \"Description of CYP2C19's primary role in the metabolic pathway of citalopram.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the recommended pindolol dose for an individual with the ADRA2C Ins/Del polymorphism?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"pindolol\", \"Gene Name\": \"ADRA2C\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf\", \"Content to Search\": \"Dose adjustment protocol for pindolol based on ADRA2C Ins/Del polymorphism.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How should phenytoin dosing be managed for a patient who is a positive carrier of the HLA-B*15:02 allele?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"phenytoin\", \"Gene Name\": \"HLA-B\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for CYP2C9 and HLA-B Genotype and Phenytoin Dosing (August 2020).pdf\", \"Content to Search\": \"Clinical recommendation for phenytoin use in HLA-B*15:02 positive patients\"}]"}]}
